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Living systems consist of one or more cells each of which plays a vital part 
in keeping the system alive. Cells in multicellular organisms thereby share 
their tasks by building different organs and tissues each with its role and 
individual processes. As these tissues are complex, dimensionality is a 
crucial consideration in biological research which encompasses: 
 Space 
 Time 
 Molecular state 
 
In particular, the study of the molecular complexity of the tissues requires 
researchers to find new ways to address the dimensionality of their research, 
as many different molecules are present within a tissue. Understanding this 
molecular complexity requires analytical chemistry to separate, identify, 
map the distribution of the individual chemical components, and investigate 
their changes over time. Therefore, dimensionality plays a key role in 
analytical chemistry, as the different aspects require either a spectral, spatial, 
or time dimension. In the spectral dimension, different molecules of a certain 
molecular class present in living systems are detected while in the spatial 
dimension the distribution of a single molecule in a living system is mapped. 
Investigation of changes in these dimensions in time makes up the time 
dimension in analytical chemistry. Although these dimensions provide 
insights into molecular complex living systems, they are limited. Multiple 
molecular classes are for instance involved in biological processes that 
require an increase in the spectral dimension to detect them all. These 
processes, in turn, take place at different histological regions inside the living 
systems necessitating an increase in the spatial dimension to map the 
distribution of the various molecules. Expanding the dimensions, both 
separate and combined is therefore needed to gain more insights into the 
molecular complexity of living systems. As biological tissues are living and 
volumetric, it is important to study the molecular complexity in vivo in the 
original three-dimensional (3D) conformation over time to be able to study 
the structural context of the sample in all dimensions. This thesis is 
essentially about studying molecular information of biological tissues in 
space (3D) over time.  
 
In biomedical research, it is difficult to have all 3 previously mentioned 




analytical tools employed in this field differ per application or research 
question and are focused on either space, time, or molecular complexity. 
Studies are, for instance, done by employing magnetic resonance imaging 
(MRI) to study changes in the brain in patients with Parkinson’s[1] or whether 
scoring of MRI features in the brain can be representative of small-vessel 
disease.[2] Other labs might use proteomics to determine differentially 
expressed proteins during disease progression or between healthy and 
disease tissue.[3, 4] Fluorescence measurements (wavelength and quenching 
measurements, in situ hybridization) can also be applied to investigate the 
relation between two genes or the interaction of proteins with membranes.[5, 
6] Although the aforementioned techniques can always be used to study 
changes over time, there is a trade-off when it comes to insights into the 
complexity in the molecular and spatial dimensions they can provide (Figure 
1). Common for proteomics and fluorescence, and most biomedical research, 
is that only a certain group of molecules is investigated or only those that are 
already known beforehand. The molecular complexity of the biological 
systems is investigated in one spectral dimension thereby not allowing a 
researcher to acquire a complete view of this complexity. Spatial information 
is needed as well as the localization of molecules inside biological systems 
can give more information about their role in biological processes. This 
spatial complexity is studied with MRI, however, this technique has a 
limitation in spatial resolution and is only applicable for a range of 
observable molecules. To gain a deeper understanding of the complexity of 
biological tissues, and have the best trade-off between all three dimensions, 
imaging techniques are needed that can map the molecular as well as the 
spatial complexity. 
 
Fig 1. Diagram showing the trade-off between the different dimensions. Indicated is where 
the standard biomedical analytical tools (proteomics (green), fluorescence (green), and MRI 




Many molecular imaging techniques, like positron emission tomography 
(PET) and near-infrared (NIR) imaging, allow the visualization of only one 
particular molecule that is known beforehand. Application of these 
techniques is targeted and they have a one-dimensional viewpoint focused 
on the molecule of interest. This is very useful for diagnostic purposes albeit 
less for research purposes where the goal often is the discovery of new 
molecules. A discovery approach is in these cases needed using techniques 
that have a multidimensional viewpoint in, for instance, the molecular 
domain allowing detection of multiple molecules.  Besides finding new 
molecules, spatial distributions of these molecules are important as well for 
biomarker discovery, investigating new classification models, or 
determining drug distributions and their metabolism. This requires a 
technique that not only has a multidimensional molecular viewpoint but also 
a spatial dimension. Mass spectrometry imaging further referred to as MSI, 
is one of those techniques that captures both the spatial complexity as well 
as the molecular complexity of biological systems (Figure 1). This duality 
makes it an advantageous additional research tool in biomedical research. 
 
 
Mass spectrometry imaging 
 
MSI is an imaging technique for which no prior knowledge about the specific 
molecules present in the sample are needed as it detects and identifies a 
plethora of molecules from a specific class that is present in the tissue.[7] The 
only knowledge needed is which class to investigate due to specific sample 
preparation protocols for every target molecular class. At the same time, MSI 
maps the spatial distribution of every detected compound. It achieves this, 
as illustrated in Figure 2, by scanning tissue sections in a pixel-by-pixel 
manner where a mass spectrum is acquired for each pixel.[8] Molecular 
distributions are reconstructed based on the intensity in each pixel after the 
selection of a molecule; the higher the intensity the brighter the color 
depicted for this pixel. In this way, the chemical make-up of the tissue 
surface is mapped and elucidated. This chemical make-up is oftentimes 
complex as different histological tissue features have their unique molecular 
profile. MSI is, therefore, an advantageous analytical tool to investigate these 






Fig 2. Overview of a general MSI workflow. The tissue section is placed on a slide and scanned 
in a pixel-by-pixel manner by an ionization source. For each pixel, a mass spectrum is 
generated that are combined into an average spectrum for the whole tissue. After acquisition, 
a single molecule can be visualized based on the intensity of said molecule in every pixel. 
 
 
MSI is a mass spectrometry-based technique. A mass spectrometer consists 
of an ionization source, a mass analyzer, and a detector.[9] MSI uses a local 
desorption and ionization process to enable spatially resolved analysis. Such 
an ionization source encompasses a desorption/ionization beam directed at 
the sample surface to locally generate ions. These ions are subsequently 
directed into the mass analyzer. Here the ions are separated based on their 
mass to charge ratio and transported to the detector to be measured. If 
enough ions with a certain m/z value hit the detector, a peak is recorded in 
the mass spectrum. This results in a mass spectrum where every detected 
mass signal can either belong to one specific molecule or multiple with 
almost similar mass. To determine whether one molecule or more is detected 
at a certain mass, a mass analyzer with a high resolving power is needed that 
can separate these small mass differences between the molecules. The height 
of the peak is a function of the concentration, ionization affinity, and ion 
suppression of this molecule in the experiment.  
 
There are many different mass spectrometry imaging techniques with 
secondary ion mass spectrometry (SIMS), matrix-assisted laser/desorption 
ionization (MALDI), and desorption ionization (DESI) MSI being the most 
commonly applied in biomedical research. These techniques rely on 
different ionization mechanisms and therefore have their own unique 






SIMS employs an ion beam to desorb and ionize the surface molecules.[10] 
These so-called secondary ions are subsequently transferred into the mass 
analyzer, commonly a time-of-flight (ToF) analyzer. As these beams can be 
focused down to a very small spot, down to 50 nm[11], SIMS is a coveted 
technique for single-cell imaging and other high spatial resolution imaging 
experiments ranging from nm to 10 µm resolution. The downside of this high 
spatial resolution is that a lot of energy hits the sample in a single-pixel 
resulting in heavy fragmentation of the ionized molecules. Over the years, 
innovative molecular primary ion beams have been developed that cause 
less fragmentation, allowing more intact biomolecules to be analyzed.[12, 13]    
 
Where SIMS uses energetic molecular ions to analyze surfaces, DESI uses 
charged solvent droplets at supersonic velocities to desorb and ionize 
molecules.[10] The composition of the solvent spray determines the detectable 
molecular classes, which are commonly metabolites and lipids. The solvent 
spray itself also determines the spatial resolution that can be achieved and is 
usually around 200 µm.[14] A drawback of using charged solvent droplets is 
that the surface gets wet and it could lead to delocalization. However, this 
can largely be prevented by optimizing the instrument settings. Another 
benefit of DESI is that it operates at atmospheric pressure, which makes it 
useful for direct analyses of tissues that cannot withstand vacuum 
conditions.  
 
The previously mentioned techniques are excellent for specific tissues or 
when high spatial resolutions are required. However, there is still a trade-off 
between spatial and molecular information. It is therefore that MALDI is the 
most employed technique in biomedical research as it can offer both high 
spatial resolutions down to the single-cell and cover the molecular 
complexity of biological tissues. Ionization in MALDI is based on laser 
desorption and ionization and requires sample surfaces to be covered with a 
fine organic crystal, termed matrix layer. This matrix crystallizes on the 
tissue surface and extracts the molecules of interest, based on the chosen 
solvent/matrix mixture. In addition, the matrix aids in the absorption of the 
laser light and ionization of the molecules incorporated into the matrix 
crystals.[10] Depended on the type of matrix applied, different molecular 
classes can be detected and visualized. The size of these matrix crystals as 




achieved. MALDI-MSI experiments are, therefore, commonly performed at 
20-50 µm spatial resolution. In recent years developments in both 
instrumentation and matrix application methods have been made allowing 
for spatial resolutions of 5 µm[15] and even 1 µm has been reported by 
Spengler and Hubert in 2002.[16] These advantages make that MALDI-MSI 
can acquire images at spatial resolutions of 1-100 µm. As MALDI-MSI allows 
researchers not only the detection of a large plethora of molecular classes but 
also the ability to choose which molecules to investigate by choosing a 
suitable matrix at high spatial resolutions, it is the most utilized MSI 
technique in biomedical research. 
 
 
Biomedical tissue for mass spectrometry imaging 
 
To be able to apply MSI in biomedical research the techniques have to be 
compatible with biomedical tissues. In most biomedical research, there are 
primarily two types of tissues used: animal or human. Before they become 
available for research purposes, they are stored and archived. When animal 
models are used, the tissues can generally be available as fresh frozen 
samples. This means that organs are directly put into liquid nitrogen to snap-
freeze them after resection from the animal, thereby stopping all biological 
processes and preventing the degradation of the sample and its molecules.[17] 
This freezing does not alter the molecules and the molecular complexity of 
the tissue is preserved. The benefit of this is that the different molecular 
classes are readily accessible for all the before-mentioned MSI techniques. 
The tissues do not require extensive sample preparation to enable the 
detection and visualization of the molecular complexity with MSI. This is 
why these types of tissues are preferred. 
 
However, clinical studies require a focus on human samples, obtained for 
instance during cancer resections. These resected cancers are typically 
scrutinized by a pathologist who will take a thin slice or more, stains the 
slice(s), and investigates if the margin of the resected material is free of 
cancerous cells. The remaining tissue of the resection cannot be discarded 
and has to be stored for a minimum amount of years according to the 
institution's respective guidelines. Pathology labs fixate the samples with 




together to prevent degradation, maintains the histology of the tissue, and 
improves the handleability by paraffin embedding, resulting in formalin-
fixed paraffin-embedded (FFPE) samples.[18, 19] As a result, samples can be 
stored at room temperature which is much cheaper and easier compared to 
long-term sample storage in a deep freezer.  
 
The molecular changes that result from these treatments make it harder for 
these samples to be measured with MSI since these chemical preservation 
steps alter the molecular information of the tissues compared to fresh frozen 
tissue. When these samples are embedded in paraffin it is even harder to 
analyze these samples as the process of embedding and its reversal results 
in the loss of certain molecular information. Some molecules, such as 
peptides and N-glycans, are demonstrated to be preserved and detectable by 
MALDI-MSI.[20, 21] These molecular classes, however, require extensive 
sample preparation steps as compared to lipid and metabolite MSI. Many 
innovative developments in sample preparation over the last decade now 
allow for routine measurements from FFPE tissues by MALDI-MSI. Even 
metabolites have been shown to be detectable from FFPE tissue.[22] 
 
The compatibility of MSI with FFPE increased biomedical investigations 
using these types of samples as they are readily available in biobanks and 
allow larger patient cohort studies. These studies are commonly done in a 
two-dimension (2D) manner where only one section per sample is imaged 
that only provides a partial representation of the complete sample. 
Biomedical tissues are volumetric with different molecular profiles 
throughout the sample as different biological processes take place at 
different parts of the tissues making it spatially complex. Also, tumors are 
known to be heterogeneous with different molecular profiles at different 
tumor regions.[23, 24] To gain more insights into this tumor heterogeneity or a 
deeper understanding of the biological processes at play in tissue and how 
they influence each other, research needs to be expanded to the complete 
tissue. Hence MSI needs to expand its spatial dimension from 2D to 3D to 
fully capture the spatial and coinciding molecular complexity of biological 








Fig 3. Visualization of a mass in a 3D volume highlighting the need for 3D-MSI. If only section 
3 (black box) was chosen the mass would have been classified as being absent in the tissue. If 
section 6 (orange box) would have been chosen it would have been classified as high 
abundant. In both cases, the statements would be incorrect as the intensity for this mass 
changes within the 3D volume. 
 
 
From two-dimensional to three-dimensional mass spectrometry 
imaging 
 
Up until recently, 3D-MSI datasets were rare as one of the bottlenecks was 
the long measuring time per section. Over the last years, instrument 
developments have resulted in faster acquisition times, higher spatial 
resolution, and broader mass ranges. The introduction of faster MSI 
techniques started a new trend in mass spectrometry imaging: three-
dimensional MSI. In MALDI and DESI, instead of one or a couple of sections 
being measured from a tissue sample, consecutive sections are measured up 
to a certain z-depth creating a 3D-MSI image. In SIMS, 3D imaging is 
achieved without sectioning. Instead, an image is generated from the surface 
and the imaged layer is sputtered away. This way a new layer is created that 
can be imaged and is unaffected by the previous image run. By alternating 
these imaging and sputtering cycles a 3D image is generated. Most of the 3D 
studies done so far have been proof-of-principle investigations. Slowly the 
applications are developing towards more biologically relevant 
investigations.  
 
These advances in instrumentation and consequential migration to 3D-MSI 
also come with their difficulties.  Samples have to be carefully prepared to 
ensure that the obtained molecular information is representative of the 




the entire 3D volume to prevent technical outliers and therefore gaps in the 
3D stack. This requires the adaption of established protocols and the 
development and inclusion of quality controls that can aid in tracking the 
reproducibility during all steps in a 3D workflow. Randomization of the 
samples to prevent batch effects is another aspect that has to be taken into 
account. Another big challenge is the amount of data that is generated and 
how to analyze them. There are no standard data analysis pipelines yet to 
determine possible technical outliers. Routine data analytics might fail to 
detect features due to a large amount of data and the large variety of features 
potentially incorporated in one 3D model. All these considerations, both in 
sample preparation and data analysis, means that experimental design is an 
important factor in 3D-MSI. The challenges resulting from increased 
dimensionality, both molecular and spatial, some of their solutions and 
applications are the central theme of this thesis.  
 
 
Scope of this thesis 
 
In this thesis, 3D-MSI in biomedical research and its challenges are 
evaluated, innovated, and applied for cohort studies. In chapter 1 an 
overview is given of recent 3D-MSI applications in biomedical research and 
experimental and data analysis considerations are being discussed. In 
chapter 2 the effect of formalin-fixation (FF) on the lipidome is investigated 
to determine whether the lipidome is still representative of the tissue. This is 
achieved by comparing a fixed mouse and rat kidney with matched unfixed 
kidneys. Alteration of certain lipid classes upon formalin-fixation was 
explored under controlled MSI conditions. The impact of these alterations on 
the ability to draw biological conclusions based on lipid data on FF tissues 
was comprehensively studied. This is relevant as FFPE tissues are often used 
in biomedical research and care has to be taken with statements based on the 
lipid data as an indication of the state of the tissue. Based on these results 
high-throughput enzymatic digestions are employed as a standard for FFPE 
MALDI-MSI in the next chapters. A big challenge in any 3D-MSI experiment 
is the data analysis due to the large amount of data gathered during these 
experiments. In chapter 3 a data analysis pipeline for 3D-MSI is therefore 
developed consisting of novel outlier detection methods to remove outliers 




determination of how many sections are required to be analyzed to be 
representative of the whole volume and their spacing. The developed data 
analysis pipeline is applied in chapter 4 where esophageal adeno-
carcinogenesis is investigated by imaging N-glycans in resections from 
patients in different stages. The obtained knowledge in the previous chapters 
leads to the valorization chapter (chapter 5) where the potential usage of 3D-
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Mass spectrometry imaging (MSI) enables the visualization of molecular 
distributions on complex surfaces. It has been extensively used in the field 
of biomedical research to investigate healthy and diseased tissues. Most of 
these MSI studies are conducted in a 2D-fashion where only a single slice of 
the full sample volume is investigated.  
 
These 2D-MSI studies most often do not give a complete overview of the 
biological processes at play in a single tissue as tissues are volumetric and 
these processes occur within the whole volume. Ideally, these biological 
processes are investigated throughout the whole volume to gain a more 
comprehensive understanding of the full spatial complexity of biological 
processes.  
 
Mass spectrometry imaging has therefore been expanded to the 3D-realm 
whereby molecular distributions within a 3D sample can be visualized. The 
benefit of investigating volumetric data has led to a quick rise in the 
application of single sample 3D-MSI investigations. As a result, experimental 
workflows and data analysis had to adapt beyond conventional 2D-MSI.  
 
In this chapter, we discuss the current state of these aspects for 3D-MSI 
studies as well as ongoing developments in light of applying 3D-MSI to 
larger patient cohorts. Although throughput is not a limitation anymore, 
data handling, processing, and analysis remain bottlenecks. These barriers 
need to be addressed to enable 3D-MSI to be routinely applied to multi-
sample studies. The experimental and data analysis considerations 
mentioned in this chapter will go a long way in guiding researchers into 
setting up their own (multi-patient) 3D-MSI studies as well as highlighting 
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Mass spectrometry imaging (MSI) is a label-free molecular imaging 
technique for which no prior knowledge about the sample is needed. It 
enables the visualization of molecular distributions on solid surfaces using 
mass spectrometry by scanning the samples in a pixel-by-pixel manner 
where for each pixel a mass spectrum is generated. Visualization of 
molecular spatial distributions provides unique insights in many fields such 
as material science and biomedical research.[10, 25] In the latter, such surfaces 
are typically thin planar sections prepared from biological tissue. MSI has 
been used extensively to image the two-dimensional (2D) distributions of 
endogenous or exogenous (drugs & pharmaceuticals) compounds in such 
planar tissue sections for the study of tissue-based diseases, tissue 
pharmacokinetics, or the study of biomaterials in medical applications.[26, 27] 
However, the natural state of the original sample is volumetric, hence 
keeping the original three-dimensional (3D) information is important to be 
able to study the structural context of the sample in all dimensions. 
 
In material science, where MSI has been employed since the 1960s[28], it is 
proven that 3D-MSI can provide essential information. Secondary ion mass 
spectrometry (SIMS), for instance, has been used extensively for 3D 
elemental analysis of semiconductors, superconductors, glass, stainless steel, 
solid oxide fuel cell components, aerospace alloys, coatings, and 
biomaterials.[29, 30] The unique capability of obtaining molecular depth 
profiles has provided evidence on how 3D-SIMS can aid in understanding 
complex volumetric structures.[31-36] 
 
The benefit of acquiring more relevant information through 3D-MSI is also 
of added value for biomedical research in which the added dimension can 
yield important contextual information about the biological tissue (see 
‘Benefits of 3D-MSI’). In conventional 2D imaging, a chemical snapshot of a 
single tissue section is generated. This snapshot corresponds to a specific 
location in a larger sample. Tissue stereology[37] has shown that a single 
section may not be representative of the whole sample. Tissues are seldom 
homogeneous, and the mix of cells across several 2D planes varies strongly, 




clinical diagnostics, the discrepancy between the sampled sections and the 
variation across a whole tissue can lead to inaccurate predictions. This occurs 
especially in oncology where cancer can be spatially very heterogeneous.[39] 
This is corroborated by the use of radiomics in oncology, which has shown 
that 3D structural features contained in clinical in vivo scans harbor relevant 
clinical information.[40] An imaging feature was found for ovarian carcinoma 
that was predictive of the outcome after the first chemotherapy. In 
glioblastoma, a specific imaging pattern was able to predict epidermal 
growth factor receptor (EGFR) overexpression. Another prime example for 
the necessity of volumetric investigation is the healthy brain which has 
therefore been the blueprint for many 3D omics studies[41] 
  
Consequentially, 3D-MSI has already analyzed a variety of solid tumor 
tissues, rodent brains, and other organs, and applications are rapidly 
increasing.[42, 43] While these studies provide successful use-cases, they also 
reveal technical aspects that require special attention and further 
development beyond conventional 2D-MSI. These aspects affect the whole 
study workflow and range from study design through sample preparation 
to data analysis. We will discuss them in this review, especially in the light 
of extending 3D-MSI to the analysis of larger sample (patient) cohorts to 
capture inter-individual effects. First, the most commonly used 3D-MSI 
techniques and their applications are briefly reviewed to illustrate the benefit 
of 3D-MSI in biomedical research. Then we highlight practical 
considerations in performing 3D experiments and 3D data analysis, as well 
as discuss the remaining challenges. 
 
 
3D approaches in MSI 
 
There are generally two different ways by which 3D-MSI can be achieved, 
depending on the desorption/ionization technique used: via surface 
sputtering or via the analysis of multiple serial sections (Figure 1). 
 
In 3D-SIMS, surface imaging and surface sputtering, where the impacting 
primary ion beam removes a nanometers-thin layer during the sputtering 
cycle, are continuously alternated until the desired depth is reached (Figure 
Experimental and data analysis considerations for three-dimensional mass 
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1A). The depth-resolution depends on the type of ion beam and the 
associated sputter rate of the region being analyzed[44-46], but usually ranges 
between 10 nm[47] and 1 nm.[48] The use of polyatomic or cluster-based ion 
beams enables small-sized biomolecules, such as lipids, to be released intact 
from the surface. Additionally, the chemical subsurface damage done by 
these beams is reduced or completely removed.[10, 49] This also allows an 
increased primary ion energy to be applied. Higher primary ion energy 
typically leads to higher secondary ion signals within a single pixel and 
results in improved image contrast.[49] The introduction of polyatomic ion 
guns, like the C60+ and Bi3+ ion guns with a smaller beam focus, even allows 
3D analysis of single cells as it can be focused down to subcellular resolution 
and generates higher yields of intact biomolecules.[49, 50] 
 
Soft-ionization techniques, in contrast, do not rely on energetic sputtering 
but rather on the soft desorption/extraction of biomolecules. In matrix-
assisted laser desorption/ionization (MALDI) and desorption electrospray 
ionization (DESI), the two most common soft-ionization techniques used for 
MSI, a 3D-image is obtained by serial measurements of consecutive sections 
from a sample (Figure 1B). The final 3D dataset is then obtained via a 
reconstruction procedure. The overall sample volume that can be analyzed 
with these techniques in a given amount of time is much higher than with 
SIMS. The analysis volume depends on the sectioning thickness (usually 10-
20 µm)[17, 51, 52],  the number of sections, and the spacing between the sections. 
MALDI and DESI are therefore often employed to measure whole tissues in 
3D as a result of the large volume of analytical capabilities. However, 
compared to SIMS, the depth-resolution between sections is limited by the 
thickness of the tissue section, which typically ranges from 4 µm (paraffin-
embedded tissue) to 12 µm (frozen tissue). Molecules within a section are 
samples from an unknown extraction depth determined by the MALDI 
matrix or DESI solvent often assumed to be constant across a sample. 
 
In MALDI-MSI, 3D applications have seen a recent rise in popularity due to 
advances in sample preparation and instrumentation, such as lasers with 
high repetition rates and fast-moving stages, which made high-throughput 
analysis possible.[15, 53, 54] As a consequence, whole tissue sections can now be 
measured within minutes, which allows a full 3D dataset to be acquired 




Compared to MALDI-MSI, DESI-MSI requires less sample preparation as no 
external matrix is required to extract the molecules of interest. This does not 
necessarily mean a higher throughput for DESI-MSI over MALDI-MSI. Due 
to a limited spray focus, DESI has a lower spatial resolution than MALDI or 
SIMS. Various efforts are ongoing to increase the lateral spatial resolution 
that would allow for the acquisition of better quality images from different 
histological regions within a tissue.[55] 
 
 
Figure 1. Schematic representation of the different approaches in 3D mass spectrometry 
imaging (MSI). (A) Secondary ion mass spectrometry (SIMS) continuously alternates imaging 
and sputtering cycles. (B) Matrix-assisted laser desorption/ionization (MALDI) or desorption 
electrospray ionization (DESI) rely on the sectioning of the sample into a stack of consecutive 
sections which are then analyzed individually and their data reassembled afterward. 
 
 
Benefits of 3D-MSI 
 
Early 3D-MSI experiments have demonstrated feasibility and have paved the 
way for subsequent applications with different ionization modalities.[56-58] 
Here, we highlight selected applications of 3D-MSI that demonstrate its 
benefit or the need to contextualize the molecular information into an 
additional spatial dimension in certain situations. 
Experimental and data analysis considerations for three-dimensional mass 





SIMS has been extensively used for 3D-MSI studies of single cells and tissues 
as reviewed by Fletcher.[34, 59] Here we highlight two applications focused on 
interfaces between drugs and surfaces. Biomaterials, like coronary stents, are 
frequently studied with three-dimensional SIMS. Coronary stents are coated 
with a polymer that contains an anti-inflammatory drug that is released over 
time to prevent blocking of the stent. To visualize the distribution of the drug 
sirolimus in a stent, drug/matrix-coated metal coupons were imaged with 
3D-SIMS.[60] A gold ion beam was used for imaging in conjunction with a 
carbon-cluster (C60) ion beam for sputtering, which results in low residual 
molecular damage after sputtering. This is needed since sirolimus is a mid-
sized (914 g/mol) pharmaceutical compound. Sputter rates have been 
determined under the same measurement conditions on a similar polymer 
material to allow accurate determination of the depth scale. It was found that 
large areas of the surface and subsurface channels were composed primarily 
of sirolimus, followed by a drug-depleted region, and lastly, a relative 
homogeneous drug distribution in the polymer matrix. Comparing these 3D 
distributions with the elution rates showed that elution occurs relatively 
quickly from the drug-enriched surface area while it proceeds more 
gradually for the subsurface regions. 
 
Supramolecular hydrogels and their capability to enhance skin permeation 
of vitamin c (ascorbic acid) and its precursor (ascorbyl glucoside) have also 
been investigated with 3D-SIMS of ex vivo porcine skin.[61] Researchers 
demonstrated that the hydrogel enhances the skin permeation of both 
compounds and preserves the conversion of the precursor into vitamin c 
until it reaches the epidermal layer, the intended target (Figure 2A). As the 
depth to the epidermis is a priori unknown and sputtering rates might change 
for each layer within a sample, the authors used two methods to calculate 
the z-resolution during sputtering. Optical profilometry was applied to 
determine the depth of the sputter craters. This provides an estimation of the 
average depth, and a phospholipid ion marker was monitored during 









The application of 3D MALDI-MSI has seen a steady increase over the past 
years. Some of these have been discussed in earlier reviews, though this is 
only a small fraction.[10, 62] Thereby missing interesting papers like the 
investigation of pathogenesis in Francisella infection by Scott et al.[63] and the 
feasibility assessment of 3D MALDI-MSI with FTICR by Jones et al.[64] One 
of the most investigated organs in the field of MALDI-MSI is the murine 
brain due to its molecular but morphologically well-charted complexity.[65, 
66] The high-lipid content in the brain, which is a molecular class well 
compatible with MALDI- or DESI-MSI, also contributes to the frequent usage 
of brain sections in MALDI-MSI. 
 
Lipid changes upon traumatic brain injury were investigated in rat brain 
with 3D MALDI-MSI to gain more understanding of the biochemical 
alterations caused by this neurological damage that is a major cause of death 
and disability in children and young adults.[67] The researchers obtained rat 
brain tissue sections every 200–250 μm covering the entire area of the 
cortical-impact injury. Tissue sections were analyzed individually using 
MALDI-MSI of lipids at 70 µm spatial resolution, resulting in a voxel size of 
70x70x220 µm in the final 3D dataset. The authors observed that certain 
lipids are specific for either the lesion site (e.g. PC (42:9) (m/z 856.598)) or the 
ventricles (e.g. PC (m/z 797.580)) that change from rostral to caudal while 
others co-localize with both regions (e.g. m/z 741.545). Acquisition of the 3D 
model helped the authors gain more insight into the changes happening 
throughout the brain since the injury-related molecules are transferred via 
these ventricles throughout the brain and other organs. The 3D results 
provided a more global view of the impact of the traumatic brain injury and 
provided insight into pathological phenomena remote from the injury site. 
 
With recent advances in instrumentation, especially in laser repetition rates, 
synchronized stage movement, and electronics, 3D-MSI datasets can now be 
generated much faster, up to 20-50 times, allowing the acquisition of 
biological or technical replicates. This was recently demonstrated by Paine 
et al., who studied medulloblastoma, the most common malignant pediatric 
brain tumor, in six mouse brains by 3D MALDI-MSI of lipids. The voxel size 
was 50x50x150 µm, and a total of 223 sections were measured in this study.[68] 
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A semi-supervised segmentation of all tissue sections was performed first to 
find the boundaries of the primary tumors to facilitate the analysis of this 
large amount of data. A comparison of metastasizing vs. non-metastasizing 
primary tumors revealed ten lipids associated with medulloblastoma 
metastasis. As these lipids were observed to be very heterogeneous in their 
distribution throughout the tumor, single section 2D-MSI could have missed 
the significance of these lipids due to sampling bias. This experiment 
demonstrated the added value of 3D-based analyses for tumor marker 
discovery and exploration. Even if multiple sections are investigated from 
one sample, it is important to prepare and analyze the sections in a 
reproducible manner to reduce inter-section technical variation. Paine et al. 
have ensured this by batch preparation (20–25 sections) and a quality 
assurance approach that involved tuning the signal intensity of each imaging 
run on the matrix to ensure similar ion yields on all sections.[68] 
 
This is especially true if MSI signals are to be compared quantitatively. For 
instance, Giordano et al. have employed 3D MALDI-MSI to quantify the 
distribution of the anti-cancer drug paclitaxel in mesothelioma tumor-
bearing mice.[69] Tumor sections were taken every 500 µm and MALDI-MSI 
experiments were performed at 100 µm lateral pixel size. The signal of 
paclitaxel was normalized to an isotopically labeled version of paclitaxel as 
an internal standard and quantified using a concentration series applied to a 
separate section. It was discovered that the distribution of the drug is 
influenced by the cellular heterogeneity of the tumor microenvironment 
showing its highest concentration at the edge of the tumor and a lower 
abundance in the center of the tumor with necrotic and fibrotic regions 
(Figure 2B). The more accurate description of the distribution of the 
compounds obtained demonstrates the added value of 3D-MSI for the 





Few studies have so far used DESI in a 3D fashion. An early 3D DESI-MSI 
study has mapped the distribution of anabolic steroid esters through bovine 
muscle tissue previously injected with these compounds.[70] The spatial 




in the z-direction by one centimeter. The 3D profile was made at the injection 
site and demonstrates that the esters are indeed inside the tissue. This 
excludes external contamination which is an important element in the 
investigation of illegal treatment of animals. 
 
In a more recent study, the unique capability of MSI to describe intra-
tumoral molecular heterogeneity has been for the first time extended to 3D 
by investigating a human colorectal adenocarcinoma biopsy by 3D DESI-
MSI at 100x100x100 μm voxel size.[42] The application of advanced data 
analysis methods including deep learning and parametric t-SNE mapping 
helped to identify tumor subgroups and characteristic metabolites that were 
not detected by classical methods such as principal component analysis 
(Figure 2C). This also exemplifies that, as the field of 3D-MSI is evolving, 
novel and advanced data analysis procedures are needed to extract all 
biological information from 3D-MSI data. 
 
 
Figure 2. Applications of 3D mass spectrometry imaging (MSI). (A) 3D SIMS-MSI was used 
to study the permeation of ascorbic acid through ex vivo skin samples after the application of 
PBS or a hydrogel. The results showed a deeper permeation when a hydrogel is used. This 
article was published in [61], Copyright Elsevier (2019). (B) Quantitative 3D MALDI-MSI of 
the anti-cancer drug paclitaxel in a malignant pleural mesothelioma tumor. Images indicate 
the drug is mostly located at the edge of the tumor. Figure adapted from [69], Licensed under 
CC BY 4.0: http://creativecommons.org/licenses/by/4.0/. (C) The application of advanced 
data analysis methods to a 3D DESI-MSI dataset of a human colorectal cancer sample revealed 
several metabolically different tumor subgroups highlighting the heterogeneity of tumors in 
three dimensions. Figure adapted from [42] - Published by The Royal Society of Chemistry. 
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3D-MSI experimental considerations 
 
The benefit of performing 3D mass spectrometry imaging also comes with 
some additional requirements and considerations in terms of sample 
preparation, experimental design, and data acquisition. The evaluation of 
these workflow elements is crucial to reliably correlate and compare findings 
throughout a 3D-MSI volume. Below, we will discuss several considerations 
that have a direct impact on the outcome of a 3D study. 
 
 
Single-cell preparation for SIMS 
 
In the case of SIMS for single-cell analysis, cells need to be prepared in such 
a way that the 3D shape and integrity of the cells are maintained. One way 
of achieving this is by chemical fixation of the cells to preserve the cellular 
architecture of the cell.[71-73] In this process of fixation, certain molecules, like 
salts, can diffuse while proteins are cross-linked together.[71, 73] Another 
approach that retains the integrity of the cells and prevents diffusion of 
molecules is to prepare frozen-hydrated cells through cryo-fixation of cells 
in their native hydrated state.[74] This method achieves higher ion yields for 
certain chemical species but requires the instrumentation to be equipped 
with a cold-stage to maintain the frozen-hydrated state of the sample 
throughout the entire workflow.[74, 75] UHV systems can result in the 
sublimation of water from the 3D samples which can subsequently 
deteriorate during cryo-imaging experiments. Alternatively, cells can be 
prepared for 3D-SIMS analyses by freeze fracturing where cells are trapped 
in a frozen sandwich, which is broken before analysis. This method 
maintains both cellular and molecular integrity but can lead to the loss of the 
top part of the cells and the fracture plane is not always reproducible. This 
makes it difficult to characterize both complementary fractured surfaces.[74, 
75] All these sample preparation methods have their advantages (e.g. 
maintaining cellular integrity, preventing diffusion) and drawbacks (e.g. 
diffusion of molecules, unreproducible fracture planes), and choosing the 






Serial section preparation 
 
In the case of 3D-MALDI and 3D DESI-MSI, experiments might require the 
collection of dozens to hundreds of (semi-)consecutive sections from one 
sample. As a result, caution is required during sectioning to exclude the loss 
of individual sections and retain the appropriate order and spacing in the 3D 
stack. Keeping the samples in the same orientation in a consistent shape will, 
later on, simplify the alignment of the sections into a 3D volume. Minor 
misalignment of sections can be digitally corrected afterward.[76] This 
registration is often based on prominent morphological features, and heavy 
distortion can render molecular images unsuitable for inclusion in the 3D 
volume. This can be overcome by embedding the tissue in embedding 
materials like optimal cutting temperature (OCT) or gelatin.[19, 52, 77, 78] Care 
has to be taken that the right embedding material is chosen, compatible with 
the measurement. Embedding with OCT is generally not recommended for 
MSI as it contains a polymer that easily ionizes in positive-ion mode and may 
cause ion suppression or mask tissue-specific signals. Synthetic polymer-
based embedding media also run the risk of smearing across tissue samples 
during sectioning.[79] Gelatin and CMC are biopolymer-based and generate 
less spectral interference, which renders them more compatible with MSI 
experiments of biological surfaces.[80] Care has to be taken that biomolecules 
do not delocalize during the embedding process. Using an embedding 
medium also allows the use of fiducial markers that can aid in the 
registration process. Fiducial markers are placed in the embedding block and 
may help to determine the position, orientation, and distortion of each 
section. They are also very suitable for use in the co-registration of MSI data 





3D-MALDI and 3D DESI-MSI experiments consist of the sequential 
measurement of serial tissue sections. If the sections or experiments have not 
been properly randomized, the entire contiguous parts of the 3D volume 
might be affected by a technical bias, which cannot be distinguished from a 
biological effect (Figure 3A). It is, therefore, necessary to use randomization 
in both sample preparation and data acquisition. Serial sections should be 
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distributed in a randomized fashion within and between the slides already 
during the sectioning process. This overcomes potential batch effects 
resulting from technical variance in slide preparation (cutting, on tissue 
chemistry, matrix application) and instrument-related batch effects such as 
a decrease or drift of system sensitivity during long runs of acquisition. 
 
While randomization itself will certainly reduce a systematic technical bias 
that can be confused with a biological effect, it will not recognize technical 
outliers. This becomes even more important when multiple 3D datasets from 
different tissues are to be measured and compared. The total project 
execution duration exceeds classical 2D-MSI projects by a factor 
corresponding to the average number of sections per 3D sample. The total 
sample preparation of a multi-sample 3D-MSI project can spread over weeks 
and months as only a single sample can usually be cut at a time. This 
increases the possibility of observing time-related batch effects between and 
within 3D-MSI datasets. A way to monitor experimental quality is the 
application and integration of quality control measurements. Quality control 
compounds can be applied before measurement or matrix application, 
thereby independently assessing either instrument performance or sample 
preparation, respectively. For instance, protein and peptide standards can be 
spotted onto the slides next to the tissue to determine matrix quality or 
digestion efficiency on a slide-by-slide basis.[84, 85] Unfortunately, this is not 
yet routinely applied in the field of 3D-MSI. Only recently, we have 
demonstrated the usefulness of quality controls to track digestion efficiency 
in a multi-patient 3D-MSI study.[85] In this study, we incorporated 
cytochrome c as quality control for digestion efficiency on a slide basis. By 
performing principal component analysis (PCA) on the cytochrome c spots 
and using a 95% error ellipse, we could identify 11 slides on which the 
digestion was insufficient. This translated to 22 sections out of a total 280 
measured giving a dropout rate of < 8%. In addition to tracking sample 
preparation quality, it is also a necessity to monitor day-to-day 
instrumentation performance as instrument sensitivity can vary from one 
experiment to another. Monitoring instrumentation performance with a 
quality control compound measured over time can assist in the identification 








Large volume measurements require careful planning of the total workflow, 
from sample preparation to data acquisition. Time can be a critical factor and 
influence the resulting 3D molecular dataset. Sample preparation should 
happen “just-in-time” before the measurements otherwise degradation of 
the samples might occur which might lead to false discoveries along the 
volume.[87, 88] Total acquisition time should be optimized to minimize the 
experimental variance within one 3D-MSI dataset while keeping throughput 
as high as possible. Dataset size is another critical factor. It increases linearly 
with the number of sections and samples and is quadratically dependent on 
the spatial resolution. The resulting total dataset size often determines the 
choice of optimal spatial resolution, the mass range, and the number of 
sections per sample. This also ensures during data analysis the various 
software packages and algorithms can read a full dataset in memory if so 
desired. We have recently proposed a procedure to determine the minimum 
number of sections needed to retain a minimum amount of the full 
information extracted from a 3D MALDI-MSI experiment.[85] This 
representativity analysis is based on calculating the correlation coefficient of 
a subset of samples to the full 3D dataset. In our study, we found that every 
third of the measured 20 sections were needed to reach a minimum 
correlation of 0.99 to the full 3D dataset. This way, a preselected, 
representative sample is defined to prospectively save sections from alike 
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Figure 3. Experimental considerations in 3D-MSI. (A) When no randomization has been 
performed, the fluctuation of the overall signal intensity across every single section, 
represented by its total ion count (TIC), can be caused by other factors such as date of the 
experiment, the slide, or the position of the section on the slide. (B) Assuming proper 
randomization and that closeby sections should have similar molecular signals, we have 
recently proposed a z-direction based regression of molecular signals. Outliers are detected 
whose molecular signals are not in line with previous and successive sections. This article was 
published in [85], Copyright Elsevier (2019). 
 
 




One of the challenges that MSI faces is the lack of a generic and reliable 
experimental outlier detection method to ensure a high degree of 
comparability for both inter- and intra-sample comparisons. Recently, we 
proposed a detection method to check for any possible outliers in 3D-MSI 
datasets. The method is based on z-directed regression analyses within a 3D 
volume and identifies sections as outliers whose molecular signals deviate 
statistically too much from the expected signal intensity (Figure 3B).[85] This 
method is generic and captures most experimental biases unless too many 
sections are affected at the same time from that bias thereby driving the 
regression analysis. This could be the case if many consecutive sections are 
on the same slide. These sections undergo all experimental steps at the same 
time and therefore all get affected by matrix application or a poor MS 





3D image reconstruction 
 
It is of interest in many studies to align and stack the individual MSI images 
of a completed 3D-MSI dataset to construct a 3D volume, which can be used 
for an advanced interpretation of the spatial context of the molecular images. 
Embedded fiducial markers can be used as reference points to automatically 
co-register and stack the single sections (Figure 4A).[81] However, the 3D 
volume reconstruction can be completed without fiducial markers. This is 
often performed manually by using either anatomical features in optical 
images that are already aligned to the MS images[89, 90] or well-structured MS 
images to spatially align the consecutive MSI slices (Figures 4B-C).[67, 68] 
These approaches are only suitable for tissues with well-defined and visible 
structures in the optical or MS images.  For the task of aligning and 
reconstructing 3D visualizations, different software applications have been 
used[58, 91-93], including ImageJ (https://imagej.nih.gov/ij/)[94], R software 
(https://www.r-project.org/), SCiLS Lab (Bruker Daltonik GmbH, Bremen, 
Germany), or Autoaligner® combined with Imaris (both from Bitplane, 
Zurich, Switzerland).[69] With Autoaligner® image features are used to align 
the sections which are built into a volume with Imaris.[92] In the case of 
ImageJ, there are different ways to align and can be done by first aligning 
stained sections using an automated rigid-body registration and then align 
the MSI images to this. With SCiLS, the sections are manually co-registered 





3D-MSI also opens the possibility of correlating the volumetric molecular 
information with data from other (3D) imaging modalities.[95] A common 
example is the combination of 3D MALDI-MSI data with standard histology 
techniques. Therefore, Lotz and coworkers analyzed 162 consecutive 
sections of an oral squamous cell carcinoma with MALDI-MSI, conventional 
hematoxylin and eosin, and immunohistochemistry. The transfer of these 
two modalities (MSI and optical microscopy) into the same coordinate 
system allowed all 3D data to be viewed next to each other, which led to a 
better understanding of the functional heterogeneity within the tumor as 
spatial context and progression can readily be determined from the H&E 
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(Figure 5A).[96] The visual integration of MSI data with data from in vivo 
imaging techniques also harbors great potential by combining the molecular 
and anatomical information from different spatial scales. In this context, 
Abdelmoula et al. developed an automatic co-registration between 3D-MSI 
and MRI that tackles the differences in spatial scales and coordinate systems, 




Spatial statistics in 3D-MSI 
 
3D-MSI data puts new demands on data analysis strategies themselves. It is 
already known in 2D-MSI that the spatial context of the single mass spectra 
is a factor that can be exploited for multivariate analyses or has to be 
accounted for when performing inferential statistical analyses. Spatial-aware 
segmentation, as reported by Alexandrov and Kobarg[98], would have to be 
extended to the clustering of voxels. Likewise, statistical approaches that 
account for the inherent spatial autocorrelation in MSI data would have to 
be extended to the third dimension.[99] Morphometric characteristics of MSI 
data have been shown by Picard de Muller et al. to carry biomedical relevant 
information, which would also have to be calculated on voxels instead of 2D 
pixels.[100] 
 
Recently, Abdelmoula et al. have translated and extended the non-linear t-
SNE dimensionality reduction to the interactive visual exploration of 3D-
MSI datasets using a hierarchical version of t-SNE. They have demonstrated 
that this approach can rapidly identify regions of interest within large high-
dimensionality 3D-MSI data sets.[101] 
 
 
Other data analysis challenges in 3D-MSI 
 
Other, less apparent data analysis challenges remain, such as the calculation 
of average spectra across a 3D volume when serial sections are not evenly 
spaced. This requires the development of a weighted average procedure that 
uses the information of the z-position of all sections that are taken into 




huge bottleneck in 2D-MSI studies, and even more so in 3D-MSI studies, as 
multiple sections need annotation. Semi-supervised learning approaches 
where partial annotations by a pathologist are combined with deep learning 
on the MSI data are proposed for the classification of the remaining tissue by 
Inglese et al.[42] If the sections are consecutive and have already been aligned 
to form a 3D model, one could also consider interpolating the partial 
annotations throughout the volume. In that light, one could also foresee the 
translation of the already existing approaches from unbiased tissue 
stereology to the molecular 3D-MSI data, where stringent sampling methods 
and geometrical and statistical principles are used to obtain accurate and 
precise three-dimensional information.[37] Ultimately, novel data analysis 
approaches need to be developed that a) will enable the researcher to extract 
the added information provided by the third dimension from a 3D-MSI 
dataset and b) does not increase the manual workload for the researcher and 
maintains it similar to the 2D-scale. 
 
 
Figure 4. Alignment strategies in tissue-section based 3D-MSI. (A) Alignment based on 
embedded fiducial markers requires a previous embedding of the sample into a medium but 
delivers good results. Adapted with permission from [81]. Copyright (2012) American 
Chemical Society (B) An alignment based on optical images requires the optical images to be 
linked to the MSI data before data analysis e.g. during the experiment. (C) Alignment based 
on only the MS images requires visible and well-defined structures in the images. The 
coarseness of these structures should match the spatial resolution of the MS images. Figure 
adapted from [68], Licensed under CC BY 4.0: 
http://creativecommons.org/licenses/by/4.0/. 
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Figure 5. Integration of 3D-MSI with other modalities. (A) A 3D MALDI-MSI dataset 
consisting of 162 consecutive sections of an oral squamous cell carcinoma was combined with 
the corresponding 3D stack of histological images. Both volumes were placed in the same 
space allowing the co-visualization of both modalities at the same depth. This article was 
published in [96], Copyright Elsevier (2017). (B) A 3D MALDI-MSI dataset of glioblastoma in 
a mouse brain was also combined with MRI. The visualization on the left shows a molecule 
that highlights the tumor area and on the right, the same ion is overlaid with the MRI image. 





Mass spectrometry imaging is an added tool for the spatially resolved 
analysis of molecules in biological tissue specimens in many fields of 
biomedical research. 3D-MSI studies are gaining momentum as the benefit 
of the added information from the 3rd dimension is slowly beginning to 
outweigh the additional experimental and post-experimental efforts. While 
the throughput is not a limitation anymore nor by sample preparation[54] nor 
by instrumentation speed[53], data handling, processing, and analysis remain 
bottlenecks. Dedicated software solutions exist but still cannot alleviate the 
additional data analysis workload that results from 3D studies. This holds 
especially true for histological annotations, spectral and image alignments, 
co-registration for integration with other imaging modalities, experimental 
outlier detection, and smart 3D visualizations. This has been recognized by 
the field shown by the many recent publications. Once these barriers are 
alleviated, 3D-MSI will be routinely extended to multi-sample studies. This 
results in a rapid three-dimensional, fully spatially aware molecular biology 
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Fresh frozen tissues are preferred for mass spectrometry imaging, however, 
these can be difficult to obtain, especially when large sample sizes like 
patient cohorts are required. Tissues that are more readily available for these 
ends are formalin-fixed paraffin-embedded (FFPE) tissues as these are 
widely used in pathology and stored in large biobanks.  
 
FFPE tissues are first fixed with formalin due to its ability to prevent tissue 
degradation and better preserve tissue morphology. By embedding the 
tissues with paraffin after fixation they can be stored long-term at room 
temperature. Although this type of tissue processing is favorable for 
pathology labs, for MSI it poses a challenge as certain classes of molecules, 
like lipids, cannot be detected anymore and tissues require longer sample 
preparation to be analyzed with MSI. 
 
Most molecular classes that are therefore analyzed on FFPE tissues with MSI 
are proteins and N-glycans. However, recently the detection of lipids and 
metabolites from formalin-fixed paraffin-embedded tissues with matrix-
assisted laser desorption/ionization mass spectrometry imaging (MALDI-
MSI) was demonstrated. This poses exciting possibilities for future studies, 
however, the resulting lipid profiles differ markedly from those typically 
generated from fresh frozen tissue.  
 
In this chapter, we want to shed light on the effects of formalin-induced 
modifications on lipids in tissues by comparing 24h formalin-fixed (FF) and 
untreated mouse and rat kidney tissues using time-of-flight MALDI-MSI 
and Fourier transform MALDI-MSI combined with tandem mass 
spectrometry.  
 
These analyses revealed distinct and class-specific depletion of ion signals of 
certain lipid species upon FF, in particular for those containing amine 
functionalities. As MSI moves closer towards clinical application and 
necessitates an increased analysis of formalin-fixed tissues our results 
provide a route to rationalize the observed tissue-dependent lipid 









Formalin fixation (FF), especially when combined with paraffin embedding, 
is the gold-standard approach for tissue preservation in pathology. The 
mechanism of preservation arises from the formalin-induced chemical 
modification of biomolecules, primarily via the reaction of formaldehyde 
with primary amines and thiols.[18] The most common outcome of this 
reaction is the crosslinking of biomolecules through the formation of 
methylene bridges which deactivates enzymatic activity enabling long-term 
storage. Despite the induced chemical modifications a variety of molecular 
analysis methods have demonstrated that FF tissues can still yield rich 
biochemical information.[102-107] 
 
The detection of lipids and metabolites has recently been demonstrated from 
formalin-fixed paraffin-embedded (FFPE) tissues using matrix-assisted laser 
desorption/ionization mass spectrometry imaging (MALDI-MSI).[22, 108] 
Importantly, the resulting spectral profiles were found to enable tissue-type 
differentiation between two renal tumor types and revealed tissue-specific 
distributions. However, the observed lipid profiles differed markedly from 
those typically generated from fresh frozen tissue, consisting of notably less 
detected lipid species than typically observed from fresh frozen tissue. These 
differences were largely attributed to lipid removal during the tissue 
processing steps that require organic solvents, as has also been reported 
using ultrahigh performance liquid chromatography.[107] However, it is 
reasonable to expect lipid alterations also originating from the fixation 
process itself.[109] Using extracts from cell cultures Cacciatore et al. reported 
that the majority of lipid species can still be detected after FF.[107] However, 
little information on the changing ion abundances and the possibility of 
class-specific depletion induced by FF was provided. Such depletion has 
previously been observed for FF brain extracts analyzed with LC-
MS/MS.[109] Furthermore, previous MSI studies have observed spectral 
changes when analyzing FF tissues compared to fresh frozen tissues[110-112], 
although broad identification based on high mass accuracy and MS/MS and 
detailed insight into the changing ion abundances of many lipid classes was 
not provided. Given the increasing role of MSI in clinical research[27, 113] and 




important to understand the alterations in lipid profiles induced by FF and 
FFPE in tissues analyzed by MSI. 
 
In this study, we explicitly investigate the effects of FF on the nature and 
abundance of lipid signals observed from mouse and rat kidney tissue using 
time-of-flight MALDI-MSI and Fourier-transform MALDI-MSI combined 
with tandem mass spectrometry. By exploiting the high mass accuracy and 
monoisotopic precursor ion selection these results unequivocally 
demonstrate the broad lipid class-specific depletion of ion signals observed 
during direct MSI analysis of untreated and FF tissues using high-
confidence, on-tissue lipid identification. They also confirm previous studies 
demonstrating high-quality MSI can be obtained for many lipid species from 
FF tissues. These results can help researchers rationalize and understand the 
observed MSI data from FF and FFPE tissue and determine if and how 







ULC/MS-CC/SFC grade methanol absolute and water was purchased from 
Biosolve Chimie SARL (Dieuze, France). Anhydrous chloroform, crystalline 
norharmane (C11H8N2), and zinc sulfate heptahydrate (99% A.C.S. reagent) 
were purchased from Sigma-Aldrich (Zwijndrecht, The Netherlands). 
Formalin fixative (3.7-4.0%) containing zinc sulfate (≤ 1% according to 
manufacturer) and acetate buffered at pH 5.6-5.8 (Unifix) was purchased 
from Klinipath BV (Duiven, The Netherlands). Indium tin oxide-coated 
conductive (ITO) glass slides (RS 4-8 Ω/sq) were purchased from Delta 
Technologies Ltd (Loveland, Colorado, USA). Hematoxylin solution 
modified according to Gill and entellan® new was purchased from Merck 
KGaA (Darmstadt, Germany). Eosine-Y, Alcholic was purchased from 
Avantor® Performance Materials B.V. (Deventer, the Netherlands), and 
coverslips were purchased from Thermo Scientific (Waltham, 
Massachusetts, USA). 
 





Two mouse kidneys were sourced from the same animal at John Hopkins 
University School of Medicine under the ethical approval by the Institutional 
Animal Care and Use Committee at the Johns Hopkins University School of 
Medicine (MO17M190). Two rat kidneys were sourced from the same rat at 
Maastricht University Medical Centre under the ethical approval by the 
institution’s review board, the Animal Ethical Committee, the Inspection for 
Animal Welfare, and the Dutch Central Committee of Animal experiments 
(AVD107002016720). All organs were snap-frozen by immediately 
transferring them into liquid nitrogen after removal and stored at -80°C until 
fixation and/or sectioning. One kidney of each animal was fixed for 24 hours 
in a zinc sulfate buffered formalin fixation solution following a standard 
pathology protocol. Prior to fixation, the tissues were first acclimated for an 
hour at -20°C after removing it from -80°C. This was followed by moving the 
sections to room temperature for an hour to ensure they were completely 
thawed before emerging them in the fixation solution.  After fixation for 24 
hours, the fixation solution was removed and the fixed kidney was stored 
back at -80°C until sectioning. The other kidney of each animal was left 
untreated and kept at -80°C until sectioning. Both fixed and untreated 
kidneys were transversally sectioned at the thickest part of the kidneys at -
20°C on a Microm HM525 cryotome (Thermo Fisher Scientific, Waltham, 
Massachusetts, USA). Sections were cut 10-12 µm thick and thaw-mounted 
onto ITO glass slides.  
 
For the MALDI-ToF measurements, slides were coated with 8 layers of 
norharmane matrix solution (7 mg/mL norharmane in 2:1 
chloroform:methanol (v:v)). An automated TM-Sprayer (HTX Technologies, 
LLC, North Carolina, USA) was used for matrix application with a flowrate 
of 0.12 mL/min, 30 seconds drying time between each layer, and a 
temperature of 30°C. Slides for MALDI-Orbitrap analysis were prepared 
using identical parameters but coated with 15 layers of norharmane matrix. 
 
After MSI slides were subsequently washed with 2 x 70% ethanol followed 
by Milli Q water for 3 minutes each before staining with hematoxylin for 3 
minutes. Excess of hematoxylin was removed with a 3-minute water wash 




water wash to remove the excess of eosin. This was followed by a 1-minute 
ethanol wash and 30 seconds xylene wash before coverslips were placed on 
top of the slides using Entellan as a mounting medium to adhere the 
coverslips to the sections. Optical images of the H&E stained tissues were 
acquired using a MIRAX scanner (Zeiss, Breda, The Netherlands). 
 
Washing of the untreated rat kidneys with zinc sulfate was performed by 
submerging a slide with rat kidney sections in a 1% zinc sulfate solution in 





All MALDI-ToF-MSI was acquired at 50 µm spatial resolution on a rapifleX 
MALDI-ToF/ToF instrument[15] (Bruker Daltonik GmbH, Bremen, 
Germany). Tissues from each kidney (mouse and rat) were analyzed in both 
negative-ion and positive-ion mode using adjacent sections for each polarity 
and data acquired in the m/z range of 200-2000. The laser scanned across a 
45x45 µm2 area using a 50x50 µm2 raster size with 200 laser shots summed 
for each position. Laser power and focus were optimized for each tissue 
section.  
 
MSI experiments at high mass resolution and accuracy were performed 
using an Orbitrap Elite Mass Spectrometer (Thermo Fisher, Bremen, 
Germany) equipped with an ion-funnel-based MALDI interface 
(Spectroglyph LLC, Kennewick, WA, USA) as recently reported.[114] Three 
untreated and FF mouse kidney sections were each measured in the 
negative-ion mode at a pixel size of 50 x 50 µm2 between m/z 200-2000. Data 
was acquired using a nominal mass resolution of 240,000 (FWHM at m/z 400), 
an injection time of 250 ms, and a laser repetition rate of 1 kHz. In addition, 
one FF and unfixed section from both mouse and rat kidney tissues were 
analyzed in positive- and negative-ion mode using the data-dependent 
acquisition (DDA)-imaging method as recently described.[115] Data was 
acquired using a stage step size of 25 x 50 µm2. This approach acquires one 
full-scan Fourier transform mass spectrometry spectrum in the Orbitrap and 
one DDA-MS/MS scan in the ion trap at each 50 x 50 µm2 area of tissue. 
Acquisition in this manner allows simultaneous acquisition of both a high 
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mass resolving power MSI dataset, accurate mass measurements of all 
detected lipids, and ion trap MS/MS spectra of lipids using monoisotopic 
precursor selection. DDA-imaging was performed in both negative-ion and 
positive-ion mode on consecutive tissue sections and data acquired within 
the m/z range 200-2000 using an ion injection time of 250 ms and a nominal 
mass resolution of 240,000 (FWHM at m/z 400) for the Orbitrap (MSI) scans. 
Typical mass accuracy was ≤ 2 ppm. Both ion activation and mass analysis 
of the fragment ions were performed in the dual pressure linear ion trap 
using resonant collision-induced dissociation (CID). In negative-ion mode 
fragmentation was performed using a normalized collision energy of 38 
(manufacturer units) and an activation q of 0.25. In positive-ion mode 
fragmentation was performed at a normalized collision energy of 30 
(manufacturer units) and an activation q of 0.17 to allow for the detection of 
the low m/z fragment ion at m/z 184 produced from PC and SM lipids.  
 
 
MSI data analysis 
 
MALDI-ToF data was imported into SCiLS software version 2016b (SCiLS 
GmbH, Bremen, Germany) for further analysis. To define regions-of-interest 
(ROIs) and extract region-specific spectra, MSI data were co-registered with 
the optical images of the post-MSI H&E-stained tissue sections.  
 
High mass resolution imaging data (excluding DDA-imaging data) was 
converted into imzML using ImageInsight software (Spectroglyph LLC, 
Kennewick, WA, USA) and imported into SCiLS software and the publically 
accessible METASPACE annotation platform.[116] Regions-of-interest (ROI) 
were manually defined by visual correlation with the H&E stained tissues. 
ROI-spectra were then extracted from the cortex and medulla regions of each 
section and loaded into mMass software[117] for peak picking and peak 
intensity determination. For MSI data visualization this data was also 
converted to mzXML format using RawConverter software[118] and 
visualized using in-house scripts for MATLAB (version R2014a, The 
MathWorks, Natick, USA) as previously described.[114]  
 
DDA-imaging data were converted to mzXML format using a 




R2014a, The MathWorks, Natick, USA) as described above and 
previously.[115] DDA-MS/MS data was analyzed using Thermo Xcalibur 





Accurate m/z values for precursor ions obtained from the DDA-imaging data 
were used to first determine the sum-composition formula of the detected 
lipid species. Supporting sum-composition fragments or those allowing  
assignment of individual acyl chains were acquired from the DDA-MS/MS 
data of the untreated tissues. Assignment of the fragments in the MS/MS 
spectra was performed using the online ALEX123 database 
(http://alex123.info/ALEX123/MS.php) and the proposed nomenclature 
by Pauling et al. for all identified fragments reported in the ALEX123 
database.[119] In some cases, several supporting fragments not reported in the 
ALEX123 databases were also observed and annotated based on prior 
literature reports.[120] 
 
Selected MS/MS measurements were performed using higher-energy 
collisional dissociation (HCD) combined with Orbitrap detection of 
fragment ions to aid in the identification of several unknown ion species. 
HCD spectra were obtained using a 1.0 Da isolation window, normalized 
collision energy of 40 (manufacturer units), and detection of fragment ions 
at a mass resolution setting of 240,000 (FWHM at m/z 400) in the Orbitrap. 
HCD-MS/MS spectra were acquired from a selected list of precursor ions 
using a 5000 ms injection time while continuously moving the stage over the 
tissue at 1 mm/sec. Data for each precursor was acquired for two minutes 
prior to spectral averaging for analysis. 
 
For both broader identification of sum-composition lipid species and 
determining the percentage contribution of each lipid class to the total 
identified lipid signal in the mouse kidney dataset the ALEX123 software 
package was used[115, 121, 122]). For each replicate, an average spectrum of each 
sample was first generated. Average spectra were then used to identify lipids 
using an m/z tolerance of ± 2.5 mDa, a relative intensity threshold of 0.1% 
base peak intensity (defined as the most intense identified lipid in the 
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averaged spectra), and searching for the following lipid classes as [M-H]- 
ions: PA, PE, PS, PI, PG, their corresponding ether and lyso variants, 
SHexCer, Cer, GM1, GM2, GM3, and CL. The percentage contribution of 
each lipid class to the total identified lipid signal was then calculated using 
Tableau Desktop version 2018.2 (Tableau Software, CA, USA). Finally, the 
percentage contribution of each class within a fixed and unfixed replicate 
was averaged to generate the final dataset. 
 
 
Results and Discussion 
 
Three transversal sections taken from both untreated and formalin-fixed (FF) 
mouse kidney tissue were analyzed using MALDI-ToF-MSI in both 
negative-ion and positive-ion mode. Analysis of this data revealed drastic 
differences in the mean spectra generated from the cortex and medulla 
regions from untreated and FF tissues (Figure 1). Spectra from individual 
sections are provided in Figures 2 and 3. In particular, the depletion of a 
variety of lipid-related peaks is observed in the negative-ion mode upon FF, 
especially in the m/z 700-850 range. We note the additional freeze/thaw cycle 
undergone by the fixed tissue is expected to have a negligible influence on 
the observation made during this study. Previous work has demonstrated 
that the primary artifact induced by repetitive freeze/thaw cycles is an 
increase in free fatty acid signals, and this effect becomes more pronounced 
with more cycles. Given only one additional freeze/thaw cycle was 
performed, and that no increase in free fatty acid signals is observed in the 













Figure 1. Mean cortex and medulla spectral comparison of the generated MALDI-ToF data 
acquired in negative-ion (A) and positive-ion (B) mode. Data was acquired from untreated 
(n=3, top, red trace) and formalin-fixed (n=3, bottom, blue trace) mouse tissues. Intensities 



















Class-specific depletion of lipid ion signals in tissues upon formalin fixation 
54 
 
Figure 2. Mean region-of-
interest spectra acquired 
in negative-ion mode 
from the cortex (left) and 
medulla (right) of each 
untreated (top, red trace) 
and formalin-fixed 
(bottom, blue trace) 
mouse kidney tissue 
sections. Intensities have 
been normalized to the 
most abundant lipid-










Figure 3. Mean region-of-
interest spectra acquired 
in positive-ion mode from 
the cortex (left) and 
medulla (right) of each 
untreated (top, red trace) 
and formalin-fixed 
(bottom, blue trace) 
mouse kidney tissue 
sections. Intensities have 
been normalized to the 
most abundant lipid-










Figure 4 shows selected ion images and narrow m/z ranges acquired from a 
single FF and untreated mouse kidney tissue sections in the negative-ion 
mode. These data reveal in greater detail the specific depletion of certain 
lipid signals upon FF. The corresponding mean spectra and MSI data from 
all replicates are provided in Figure 5 and are consistent with the data shown 
in Figure 4. Figures 4A-C show example ion distribution images and spectral 
ranges that show little alteration upon FF. Importantly, and in line with 
earlier reports[22, 110, 111], consistent ion images are observed from both fixed 
and unfixed tissues indicating that the solvent-based fixation process does 
not significantly alter the spatial distributions of lipids detectable in FF 
tissues. In contrast, Figures 4D and 4E show example ion images and spectral 
ranges acquired in the negative-ion mode that are significantly depleted 
upon FF (e.g., m/z 766.5 and 810.5). Several ions are also observed at higher 
abundance upon FF, for example, m/z 799.5 shown in Figure 4F, which is 
observed primarily from the cortex regions of the kidney. Analogous 
changes are also observed in identically-treated rat kidney tissues (Figures 6 
and 7). The potential influence on the obtained spectra by the zinc sulfate 
present in the fixation solution was also investigated. Spectra acquired from 
fresh frozen tissue with and without washing in 1% aqueous zinc sulfate 
solution are provided in Figure 8. Although a strong desalting effect was 
observed in the washed tissue leading to a reduction of [M+Na]+ and [M+K]+ 
ions, crucially, the detected lipid species and classes were very similar, 
providing evidence the observed spectral changes are not the result of the 
zinc sulfate within the fixation solution.  
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Figure 4. Selected m/z ranges and ion images in the negative-ion mode that were (A-C) not 
significantly altered upon fixation, (D, E) depleted upon fixation, and (F) enhanced upon 
fixation of the mouse kidney tissue. Spectra represent the average signal acquired from all 
three technical replicates while one representative MSI dataset from each fixed and unfixed 
dataset is shown. All spectra have been normalized to their base peak and all images 
normalized to the total-ion-current and generated using hotspot removal (quantiles of the 
image have been calculated between 0-99.0%). MSI data correspond to the labeled peak in 
each case and the optical image of the post-MSI H&E stained tissue is provided adjacent to 
the MSI data (note some distortion of the fixed tissues during H&E staining was observed. 
This distortion was not observed in the optical image of the sample prior to MSI, neither is it 
observed in the MSI data itself. This post-MSI distortion thus does not influence the acquired 
spectra data. ROI’s are consistent with the optical images acquired prior to MSI where cortex 










Figure 5. Selected m/z ranges 
and ion images of all three 
mouse kidney replicates 
acquired in the negative-ion 
mode that were (A-C) not 
significantly altered upon 
fixation, (D, E) depleted upon 
fixation, and (F) enhanced upon 
fixation. Spectra represent the 
average signal acquired from all 
three technical replicates. All 
spectra have been normalized to 
the base peak of each 
corresponding data and all 
images normalized to the total-
ion-current and generated using 
hotspot removal (quantiles of 
the image have been calculated 
between 0-99.0%). MSI data 
correspond to the labeled peak 




Figure 6. Mean spectral 
comparison of the 
generated MALDI-ToF 
data acquired in (A) 
negative-ion and (B) 
positive-ion mode. Data 
was acquired from 
untreated (n=3, top, red 
trace) and formalin-
fixed (n=3, bottom, blue 
trace) rat tissue sections. 
Intensities have been 
normalized to the most 
abundant lipid-related 
peak in each spectrum 
and intensities from 
each tissue averaged 
across the entire 
measurement region. 
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Figure 7. Selected m/z ranges and 
ion images of all three rat kidney 
replicates acquired in the 
negative-ion mode that were (A-
C) not significantly altered upon 
fixation, (D, E) depleted upon 
fixation, and (F) enhanced upon 
fixation. Spectra represent the 
average signal acquired from all 
three technical replicates. All 
spectra have been normalized to 
the base peak of each 
corresponding data and all 
images normalized to the total-
ion-current and generated using 
hotspot removal (quantiles of the 
image have been calculated 
between 0-99.0%). MSI data 





Figure 8. Mean spectral 
comparison of the 
generated MALDI-ToF 
data acquired in (A) 
negative-ion and (B) 
positive-ion mode from 
fresh frozen tissue 
unwashed (top, red trace) 
and washed with aqueous 
1% zinc sulfate solution 
(bottom, blue trace). Peaks 
originating from the 1% 
zinc sulfate are marked 










The above results provide evidence of class-specific lipid depletion of ion 
signals upon FF. To elucidate the specific lipid classes affected by FF we 
further analyzed both FF and fresh frozen mouse and rat kidney tissues 
using high mass resolution MALDI-MSI and MS/MS. Figure 9 shows the 
average ion intensities for a variety of lipid species detected in the cortex and 
medulla regions of three untreated and FF mouse kidney sections. MS/MS 
data supporting the molecular-lipid species lipid identifications are 
provided in Figures 10-15. As these comparisons are made from the same 
tissue regions comprising the same original composition, the observed 
differences must arise via FF-induced processes. Figures 9A and 9B show the 
intensities of several phosphatidylethanolamines (PE) and 
phosphatidylserines (PS) lipid species. Both PE and PS lipids show a 
dramatic and statistically significant reduction in signal intensity after FF 
that is consistent with prior observations using both MSI and LC-MS/MS[109, 
110] and the known mechanism of formalin fixation. More specifically, 
formalin reacts with the primary amine groups of the PE and PS headgroups, 
effectively cross-linking the lipids with other amine-containing lipids and 
proteins. This crosslinking is hypothesized to inhibit the extraction of free 
lipids into the matrix and their subsequent ionization by MALDI. 
Phosphatidic acid (PA) species show a varied response upon fixation (Figure 
9C). The ions corresponding to [PA(18:0_18:1)-H]- and [PA(18:0_22:4)-H]- 
remaining relatively unaffected by fixation. This can be rationalized by the 
lack of an amine group in PA lipids. In contrast [PA(18:0_20:4)-H]- shows an 
apparent ~2 fold reduction upon FF. This result is initially surprising due to 
the lack of an amine group that can undergo crosslinking. However, PA 
lipids can also form via in-source fragmentation of other phospholipids, 
most significantly from PS lipids following the loss of the serine headgroup 
(-87 Da). Thus part of the [PA(18:0_20:4)-H]- ion population likely arises from 
the abundant [PS(18:0_20:4)-H]- species that is reduced upon FF (Figure 9B). 
Thus results for PA lipids reflect a convolution of both endogenous PA lipids 
and those arising from in-source fragmentation of other lipid species. 
Phosphatidylinositol (PI) lipids showed a ~2-fold reduction after FF (Figure 
9D). We speculate this is due to either minor degradation of endogenous 
lipids during the fixation process and/or partial reaction of the hydroxyl 
groups of PI with formalin. Phosphatidylglycerol (PG) remains largely 
unaffected by fixation (Figure 9E). This is in contrast to previous work that 
has reported both a decrease[109] and an increase[110] in PG ion intensities after 
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FF, although we note we only observed one PG species at sufficient intensity 
for analysis. Interestingly both sulfatides (SHexCer, Figure 9F) and 
cholesterol sulfate (CholS, Figure 9G) exhibited higher intensities after FF 
within the medulla. This observation can possibly be explained by an 
increase in ionization efficiency, resulting from the decreased amounts of 
other phospholipids classes that may lead to charge competition and 
ionization suppression. A similar effect resulting in increased signals for 
glycosphingolipids following removal of phospholipids using a 
phospholipase C digestion protocol has been reported previously by Vens-
Cappell et al.[123] 
 
 
Figure 9. Barplot comparison of the absolute ion intensities acquired from the cortex and 
medulla of fixed and unfixed mouse kidney tissue sections (n=3 each) for selected lipid 
species representative of seven different lipid classes. (A) phosphatidylethanolamine (PE), (B) 
phosphatidylserine (PS), (C) phosphatidic acid (PA), (D) phosphatidylinositol (PI), (E) 
phosphatidylglycerol (PG), (F) sulfatide (SHexCer), and (G) cholesterol sulfate (CholS). 
Significant changes (P < 0.05) between the untreated and the fixed tissues are indicated using 




Figure 10. Ion trap MS/MS spectra of deprotonated PE lipid species acquired from an 
untreated mouse kidney tissue section. Lipids are identified as (A) [PE(16:0_20:4)-H]-, (B) 
[PE(18:1_20:4)-H]-, and (C) [PE(18:0_20:4)-H]-. Full-scan MS1 data acquired in the Orbitrap 
was used to determine the precursor ion m/z and assign sum-composition formula based on 
the high mass accuracy measurement. The MS/MS spectra acquired in parallel in the ion trap 
using resonance CID was then used to identify the dominant molecular lipid species. It is 
likely additional isobaric and isomeric lipids are also co-isolated and fragmented giving rise 
to additional peaks in the MS/MS spectra. 
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Figure 11. Ion trap MS/MS spectra of deprotonated PS lipid species acquired from an 
untreated mouse kidney tissue section. Lipids are identified as (A) [PS(16:0_20:4)-H]-, (B) 
[PS(18:0_18:1)-H]-, and (C) [PS(18:0_20:4)-H]-. Full-scan MS1 data acquired in the Orbitrap was 
used to determine the precursor ion m/z and assign sum-composition formula based on the 
high mass accuracy measurement. The MS/MS spectra acquired in parallel in the ion trap 
using resonance CID was then used to identify the dominant molecular lipid species. It is 
likely additional isobaric and isomeric lipids are also co-isolated and fragmented giving rise 








Figure 12. Ion trap MS/MS spectra of deprotonated PA lipid species acquired from an 
untreated mouse kidney tissue section. Lipids are identified as (A) [PA(18:0_18:1)-H]-, (B) 
[PA(18:0_20:4)-H]-, and (C) [PA(18:0_22:4)-H]-. Full-scan MS1 data acquired in the Orbitrap 
was used to determine the precursor ion m/z and assign sum-composition formula based on 
the high mass accuracy measurement. The MS/MS spectra acquired in parallel in the ion trap 
using resonance CID was then used to identify the dominant molecular lipid species. It is 
likely additional isobaric and isomeric lipids are also co-isolated and fragmented giving rise 
to additional peaks in the MS/MS spectra. 
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Figure 13. Ion trap MS/MS spectra of deprotonated PI lipid species acquired from an 
untreated mouse kidney tissue section. Lipids are identified as (A) [PI(16:0_20:4)-H]-, (B) 
[PI(18:0_18:2)-H]-, and (C) [PI(18:0_20:4)-H]-. Full-scan MS1 data acquired in the Orbitrap was 
used to determine the precursor ion m/z and assign sum-composition formula based on the 
high mass accuracy measurement. The MS/MS spectra acquired in parallel in the ion trap 
using resonance CID was then used to identify the dominant molecular lipid species. It is 
likely additional isobaric and isomeric lipids are also co-isolated and fragmented giving rise 






Figure 14. Ion trap MS/MS spectra of a deprotonated PG lipid species acquired from an 
untreated mouse kidney tissue section. Lipid is identified as [PG(16:0_18:1)-H]-. Full-scan MS1 
data acquired in the Orbitrap was used to determine the precursor ion m/z and assign sum-
composition formula based on the high mass accuracy measurement. The MS/MS spectra 
acquired in parallel in the ion trap using resonance CID was then used to identify the 
dominant molecular lipid species. It is likely additional isobaric and isomeric lipids are also 
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Figure 15. Ion trap MS/MS spectra of deprotonated sulfatide lipid species acquired from an 
untreated mouse kidney tissue section. Lipids are identified as (A) [SHexCer(22:0;1_18:1;2)-
H]-, (B) [SHexCer(23:0;1_18:1;2)-H]-, and (C) [SHexCer(24:0;1_18:1;2)-H]-. Full-scan MS1 data 
acquired in the Orbitrap was used to determine the precursor ion m/z and assign sum-
composition formula based on the high mass accuracy measurement. The MS/MS spectra 
acquired in parallel in the ion trap using resonance CID was then used to identify the 
dominant molecular lipid species. It is likely additional isobaric and isomeric lipids are also 










From a broader lipidomics perspective, Figure 16 shows the changes in 
relative contributions to the total identified sum-composition lipid signal 
(cf., “Lipid Identification” section in the Methods) obtained from both fixed 
and unfixed mouse kidney tissues in the negative-ion mode MS1 data (i.e., 
lipids are assigned based on accurate m/z values). The full list of identified 
sum-composition lipid species is provided in Supporting Information Table 
S1 (https://doi.org/10.1016/j.ijms.2019.116212). Consistent with the above, 
Figure 16 shows an increased contribution from sulfatides and a reduced 
contribution from a variety of lipid species, in particular PI, PE, and PS 
species. We note that the relative decrease in PE species appears to be less 
than that shown in Figure 9. This is due to the MS1-based identification 
routine incorrectly assigning several ions originating from the in-source 
fragmentation of PC species to their corresponding [M-CH3]- ions as isomeric 
deprotonated PE lipids. For example, based only on accurate mass m/z 
718.5386 is assigned as [PE(34:0)-H]-. However, MS/MS data reveals an 
almost exclusive presence of 16:0-related fragments, suggesting this ion is 
instead [PC(32:0)-CH3]- (data not shown). Figure 17 shows the 
corresponding ion distribution images for all species discussed above in 
Figure 9 and reveals consistent ion distributions for all lipid species observed 
in both untreated and FF tissues. For interested readers the  complete  
negative-ion mode datasets from each mouse kidney replicate can be 
accessed via the METASPACE online annotation platform 
(https://metaspace2020.eu/).[124] Similar class-dependent depletion of lipid 
signals was also obtained in rat kidney tissue sections (Figures 18 and 19). 
 
 
Figure 16. Barplot showing the changes in the contribution of lipid classes to the total 
identified lipid signal (cf., “Lipid Identification” section in the Methods) from fixed and 
unfixed mouse kidney tissue (n=3 each). Error bars represent ± 1 standard deviation. 
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Figure 17. MALDI-Orbitrap ion distribution images for the lipid species shown in Figure 9. 
Each image has been normalized per-pixel to the total ion count and plotted against the 
maximum normalized intensity observed from the untreated (fresh frozen) tissues, with the 
exception of SHexCer and CholS images that are plotted against the maximum normalized 












Figure 18. Barplot comparison 
of the absolute ion intensities 
acquired from fixed and 
unfixed rat kidney tissue 
sections (n=1) for selected lipid 
species representative of seven 
different lipid classes. 
Intensities are the average 
across the entire tissue region. 
(A) phosphatidylethanolamine 
(PE), (B) phosphatidylserine 
(PS), (C) phosphatidic acid (PA), 
(D) phosphatidylinositol (PI), 
(E) phosphatidylglycerol (PG), 
(F) sulfatide (SHexCer), and (G) 







Orbitrap ion distribution 
images for the lipid 
species shown in Figure 
18 from both fixed and 
untreated rat kidney 
tissue. Each image has 
been normalized per-
pixel to the total ion 
count and plotted 
against the maximum 
normalized intensity 
observed for the 
untreated (fresh frozen) 
tissues, with the 
exception of SHexCer 
and CholS images that 
are plotted against the 
maximum normalized 
intensity observed for 
the FF tissues. 
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An interesting observation in negative-ion mode was the presence of the 
[M+HSO4]- adducts for sphingomyelin (SM) in the fixed mouse and rat 
kidney tissue. From mouse kidney tissue, these ions were observed in the 
Orbitrap data at m/z 799.5274 and m/z 911.6524 (m/z 799.5 is also shown in 
Figures 1 and 4). The measured m/z values provided in the high-resolution 
Orbitrap analysis yielded no logical matches in either the LIPIDMAPS 
database or the ALEX123 lipid calculator. However, HCD-MS/MS spectra for 
these ions (Figures 20-23) revealed a sole fragment ion at m/z 96.9603 for both 
precursors which was assigned to the HSO4- anion (mass errors ≤ 2.5 ppm). 
This anion formed following neutral losses of 702.5662 and 814.6909 from the 
precursor ions at m/z 799.5274 and 911.6524, respectively. These neutral 
losses correspond to the neutral masses of the sphingomyelin (SM) species 
SM 34:1;2 and SM 42:1;2 (-2.8 ppm and -3.0 ppm), respectively, providing 
strong evidence for the assignment of these ions as [M+HSO4]- ions of these 
SM lipids. The source of the hydrogen sulfate is likely from the zinc sulfate-
containing formalin solution. The ability to detect SM lipids in the negative-
ion mode, in addition to the more acidic sphingolipids such as SHexCers, 
can allow the direct correlation of their distributions within a single dataset 
that could serendipitously prove beneficial in the study of sphingolipid 
metabolism. 
 
Taken together, the above results rationalize the observations in the initial 
MALDI-ToF data shown in Figures 1 and 4. In Figure 4 the presence of ions 
at m/z 837.5, 861.5, and m/z 878.5 that are not massively depleted upon FF is 
observed. Using the DDA-imaging data these ions are identified as 
[PI(16:0_18:1)-H]-, [PI(18:0_18:2-H]-, and [SHexCer(22:0;1_18:1;2)]-, 
respectively and are lipid classes that do not contain an amine group and are 
thus expected to be tolerant to FF. On the other hand, the ions observed at 
m/z 766.5 and m/z 810.5 (Figures 4D and 4E) are identified as [PE(18:0_20:4)-
H]- and [PS(18:0_20:4)-H]- ions, respectively. These both correspond to 
amine-contacting lipids and their signal depletion is consistent with the 
known mechanisms of fixation. Finally, as described above, the ion detected 
at m/z 799.5 in Figure 4 is assigned as a [M+HSO4]- ion of SM 34:1;2 and is an 







Figure 20. Identification of 
[SM(34:1;2)+HSO4]- in the 
negative-ion mode analysis of 
formalin-fixed mouse kidney 
tissue. HCD-MS/MS of the m/z 
799.5265 precursor ion 
demonstrating the formation of 
an HSO4- fragment 
corresponding to the neutral loss 
of SM(34:1;2).   
 
Figure 21. Identification of 
[SM(42:1;2)+HSO4]- in the 
negative-ion mode analysis of 
formalin-fixed mouse kidney 
tissue. HCD-MS/MS of the m/z 
911.6515 precursor ion 
demonstrating the formation of 
an HSO4- fragment 
corresponding to the neutral loss 
of SM(42:1;2). 
 
Figure 22. Identification of 
[SM(34:1;2)+HSO4]- in the 
negative-ion mode analysis of 
formalin-fixed rat kidney tissue. 
HCD-MS/MS of the m/z 799.5266 
precursor ion demonstrating the 
formation of an HSO4- fragment 




Figure 23. Identification of 
[SM(42:1;2)+HSO4]- in the 
negative-ion mode analysis of 
formalin-fixed rat kidney tissue. 
HCD-MS/MS of the m/z 911.6515 
precursor ion demonstrating the 
formation of an HSO4- fragment 
corresponding to the neutral loss 
of SM(42:1;2). 
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In the positive-ion mode, the combined high mass accuracy and MS/MS 
measurement enabled the differences shown in Figure 1B to be identified. As 
expected positive-ion mode spectra were dominated by PC and SM lipids in 
both FF and untreated tissues. Although at first look the spectra appear 
similar, being dominated by abundant [M+H]+ ion in both cases, an increase 
in alkali adducts, most notably [M+Na]+ ions, is also observed in the 
untreated tissues. The shift towards protonated ions in the fixed mouse and 
rat tissue is attributed to the aqueous fixation solution which effectively 
removes endogenous sodium and potassium from the tissue. This effect is 
analogous to studies utilizing aqueous washing to desalt tissues prior to 
MSI[125, 126] and is consistent with work demonstrating a shift in adduct 
formation of PC lipids before and after fixation, with the specific shift 
depending on the composition of the formalin fixation solution.[110, 111] 
However, [M+Na]+ and [M+H]+ adducts of different PC lipid species can 
remain unresolved even with the high mass resolving power realized here. 
To demonstrate the shift towards protonated species in the FF tissue we have 
analyzed the CID-MS/MS spectra acquired from precursor ions of m/z 782.57 
and m/z 810.60 in both positive-ion mode datasets. These two ion 
populations represent isobaric combinations of [PC 36:4 +H]+/[PC 34:1 
+Na]+ and [PC 38:4 +H]+/[PC 36:1 +Na]+ respectively. In the untreated 
tissue, both the 59 and 183 neutral loss fragments are observed at high 
abundance and are attributed to the losses of N(CH3)3 (-59 Da) and 
phosphocholine (-183 Da) respectively (Figures 24A, 25A (from mouse 
tissue) and 26A, 27A (from rat tissue)). These fragment ions are known to 
form to a far greater extent for alkali adducted PC lipids compared to their 
protonated variants[127], thereby providing evidence for a significant 
population of [M+Na]+ ions. By contrast, in the fixed tissue the m/z 184 
fragment is formed almost exclusively and is the main expected fragment 
from protonated PC lipids (Figures 24B, 25B (from mouse tissue) and 26B, 
272B (from rat tissue)). These data demonstrate that FF does not significantly 
influence the detection of PC and SM lipids in positive-ion mode but simply 
results in a shift in adduct profile. In this case, this results in the almost 







Figure 24. Ion trap MS/MS spectra of a selected PC-related ion observed at m/z 782.57 in the 
positive-ion mode acquired from (A) untreated mouse kidney tissue section and (B) fixed 
mouse kidney tissue section. Full-scan MS1 data acquired in the Orbitrap was used to 
determine the precursor ion m/z and assign sum-composition formula based on the high mass 
accuracy measurement. The MS/MS spectra acquired in parallel in the ion trap using 
resonance CID was then used to identify the dominant molecular lipid species. In the 
untreated tissue fragments suggesting the presence of both [PC(34:1)+Na]+ (m/z 723.3 and m/z 
599.4) and [PC(36:4)+H]+ (m/z 184) are observed. In the fixed tissue a far greater contribution 
from [PC(36:4)+H]+-related fragments is observed which is attributed to the removal of salts 
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Figure 25. Ion trap MS/MS spectra of a selected PC-related ion observed at m/z 810.60 in the 
positive-ion mode acquired from (A) untreated mouse kidney tissue section and (B) fixed 
mouse kidney tissue section. Full-scan MS1 data acquired in the Orbitrap was used to 
determine the precursor ion m/z and assign sum-composition formula based on the high mass 
accuracy measurement. The MS/MS spectra acquired in parallel in the ion trap using 
resonance CID was then used to identify the dominant molecular lipid species. In the 
untreated tissue fragments suggesting the presence of both [PC(36:1)+Na]+ (m/z 751.4 and m/z 
627.4) and [PC(38:4)+H]+ (m/z 184) are observed. In the fixed tissue a far greater contribution 
from [PC(38:4)+H]+-related fragments is observed which is attributed to the removal of salts 













Figure 26. Ion trap MS/MS spectra of a selected PC-related ion observed at m/z 782.57 in the 
positive-ion mode acquired from (A) untreated rat kidney tissue section and (B) fixed rat 
kidney tissue section. Full-scan MS1 data acquired in the Orbitrap was used to determine the 
precursor ion m/z and assign sum-composition formula based on the high mass accuracy 
measurement. The MS/MS spectra acquired in parallel in the ion trap using resonance CID 
was then used to identify the dominant molecular lipid species. In the untreated tissue 
fragments suggesting the presence of both [PC(34:1)+Na]+ (m/z 723.6 and m/z 599.6) and 
[PC(36:4)+H]+ (m/z 184) are observed. In the fixed tissue a far greater contribution from 
[PC(36:4)+H]+-related fragments is observed which is attributed to the removal of salts from 
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Figure 27. Ion trap MS/MS spectra of a selected PC-related ion observed at m/z 810.60 in the 
positive-ion mode acquired from (A) untreated rat kidney tissue section and (B) fixed rat 
kidney tissue section. Full-scan MS1 data acquired in the Orbitrap was used to determine the 
precursor ion m/z and assign sum-composition formula based on the high mass accuracy 
measurement. The MS/MS spectra acquired in parallel in the ion trap using resonance CID 
was then used to identify the dominant molecular lipid species. In the untreated tissue 
fragments suggesting the presence of both [PC(36:1)+Na]+ (m/z 751.6 and m/z 627.6) and 
[PC(38:4)+H]+ (m/z 184) are observed. In the fixed tissue a far greater contribution from 
[PC(38:4)+H]+-related fragments is observed which is attributed to the removal of salts from 














Using MALDI-MSI combined with accurate mass measurements and 
MS/MS we have systematically investigated the effect of formalin fixation 
on lipids in kidney tissue, a widely used model tissue for MSI studies. In line 
with the known crosslinking mechanism of formalin, our results show a 
significant depletion of ion signals from primary amine-containing 
phospholipids, namely PE and PS that is consistent with earlier reports.[109, 
110] We did not observe potential intermediate reaction products of the 
fixation process such as N-formylation N-methylation as previously 
reported for LC-MS[109] or cross-linked lipid species. The latter observation 
can be rationalized by the generation of a cross-linked network of lipids and 
proteins. Although the depleted lipids only contain a single amine group 
they may still form an interconnected covalent network with other cross-
linked species that is not efficiently extracted into the matrix, ionized, and 
that exceeds the accessible mass range. It is noteworthy that despite the 
solvent-based fixation procedure high-quality MSI data can still be acquired 
from fixed tissues for many different classes with minimal delocalization 
compared to unfixed tissues (e.g., Figures 4 and 17). The potential recovery 
of cross-linked lipids by optimized antigen retrieval steps may provide an 
exciting future avenue of research to increase the lipid coverage achievable 
when analyzing FF tissues.  
 
FF is not used in isolation, but routinely in combination with paraffin 
embedding (FFPE tissues). Given the recent demonstration of lipid detection 
from clinically-relevant FFPE tissues using MALDI-MSI and the potential 
diagnostic power of such analyses[22] our results can help rationalize the 
detected lipid species in these applications (independent of potential losses 
arising from the paraffin embedding process itself) and provide insight into 
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MSI has become a powerful tool in biomedical research to investigate the 
distribution of a broad scale of compounds ranging from metabolites to 
proteins as well as drugs in diseased tissues, such as malignant tumors. MSI 
is most commonly applied in a 2D fashion but in recent years 3D-MSI has 
been more applied in the field to gain a deeper understanding of biological 
processes underlying diseases. 
 
These 3D applications are potentially introducing a sampling bias on a 
sample or patient level, respectively. As more tissues are imaged per patient 
to obtain a 3D volume, and this is amount is multiplied per patient included 
in the study, not only a large dataset is obtained but it requires also more 
sample preparation and measurements. This increase in sample handling 
can lead to sampling bias and discrepancies due to insufficient 
reproducibility.  
 
In this chapter, we aim to investigate the consequences of sampling bias on 
sample representativeness. We, therefore, analyzed fourteen bladder cancer 
patients with varying histological grades with 3D MALDI-MSI by digesting 
20 sections per patient with trypsin to obtain peptides. To obtain 
reproducible results we incorporated a quality control in the sample 
preparation. This quality control was used in one of the two novel outlier 
detection routines we developed for 3D-MSI data to evaluate digestion 
efficacy. The other outlier detection was based on z-directed regression and 
both outlier detections combined led to 20% of the data being classified as 
outliers and were subsequently removed. 
 
After removing the data it was found that 33% of a sample has to be 
measured to obtain sufficient coverage of the existing biological variance 
within a tissue sample. Furthermore, we investigated what the consequence 
of sampling bias is on the precision of biomarker discovery for histological 
grading of human bladder cancers by MSI.  
 
  





Mass spectrometry imaging (MSI) has emerged as a powerful tool in 
biomedical research to reveal the localization of a broad scale of compounds 
ranging from metabolites to proteins in tissues in a label-free manner.[113] 
Especially in cancer research, MSI enables scientists and pathologists to look 
at how molecules are distributed both between tumors and within tumors in 
order to shed light on tumor biology or find potential biomarkers for e.g. 
tumor staging.[128] So far, MSI is most often deployed as a two-dimensional 
(2D) imaging technique. However, this can pose limitations when studying 
typically heterogeneous tissues since a complete overview of the three-
dimensional context of the tissue is not retained in a single section. With 
recent improvements in acquisition speed and data analysis, three-
dimensional (3D) MSI is coming to the forefront whereby data from multiple 
consecutive 2D sections are combined into a 3D volume.[129] 
 
The first report on 3D-MSI was by Crecelius et al.[56], in which they visualized 
the distribution of myelin basic protein (MBP) in a mouse brain. In later 
years, articles have been published where neuropeptides and lipids were 3D 
visualized in a Crustacean brain[80] and neuropeptides and proteins in a 
mouse brain.[43] Furthermore, 3D-MSI has been used to visualize cancer drug 
distribution in tumors, which allowed the authors to confirm the relation of 
the structural heterogeneity of the microenvironment with the drug 
distribution inside tumors.[69] Patterson et al. also used 3D-MSI to study the 
molecular distribution of lipids in atherosclerotic plaques.[93] This paper 
clearly shows the added value of 3D over 2D, since the authors found several 
lipids that correlated with the degree of artery stenosis, the volumetric 
narrowing of the artery.   
 
All these examples show the potential of 3D-MSI for biomedical research. 
However, all 3D-MSI studies to-date have so far only investigated a single 
fresh frozen tissue given the heavy experimental workload of 3D-MSI 
studies. This has two drawbacks: first, fresh frozen specimens are not readily 
available in a clinical setting; and second, the results from a single tissue lack 





Tissues that are available for this purpose are formalin-fixed paraffin-
embedded (FFPE), which are stored in large biobanks worldwide. Even 
though MSI sample preparation methods exist for FFPE tissues[130-132], they 
have not yet found usage for 3D-MSI. The main reason for this is the 
experimental workload and the challenge to guarantee reproducibility over 
multiple sections from the same sample and between different samples.[84] 
 
In this work, we report on the usage of matrix-assisted laser 
desorption/ionization (MALDI)-MSI for the acquisition of 3D-MSI datasets 
from fourteen human bladder cancer resection specimens provided as FFPE 
samples. Bladder cancer is a common cancer type, especially amongst 
men.[133] In bladder cancer, the distinction between high- and low-grade 
urothelial carcinoma is important since high-grade bladder cancer has a high 
chance of recurrence and progression.[134] 2D-MSI can assist in differentiating 
these grades, as previously reported by Oezdemir et al. in 2012 by measuring 
proteins from fresh frozen tissues.[135] Taking into consideration tumor 
heterogeneity in bladder cancer, as in many cancers[23], this method may fall 
short of precise representation of the disease state. Particularly, to assess the 
extent of the disease which mainly includes the level of invasion, if any, 
makes multi-site sampling or 3D analyses of the samples imperative for a 
comprehensive characterization of the tumor.[136]  
 
In our study, we used FFPE tissue of bladder cancer resections to obtain 
molecular information on a peptide level by in situ proteolytic digestion on 
the tissues’ surface which is widely used in clinical MSI studies.[20, 137, 138] A 
key aspect of our sample preparation protocol was the implementation of 
several quality controls designed to monitor the reproducibility over all 
datasets. The obtained data allowed an extensive investigation of the nature 
of 3D-MSI datasets including outlier detection, the effect of sampling bias, 
and the minimum set of representative sections. The presented study is the 
first report on 3D-MSI of tryptic peptides from multiple FFPE tissues and 
proposes a comprehensive data analysis workflow for this type of data. 
  







FFPE bladder cancer resection specimens of fourteen patients were analyzed 
in this study. Per patient, 40 consecutive sections with a thickness of five µm 
were sampled of which every second section was provided on indium tin 
oxide-coated conductive (ITO) glass slides (Delta Technologies, Loveland, 
USA) by the Amsterdam Medical Center (Amsterdam, Netherlands) with 
two sections per slide. The section size varied per patient (Figure 1A) and 
was on average 24.29 mm2 (Table 1). The patients gave their informed 
consent and the study was approved by the Institutional Review Board of 
the Amsterdam Medical Center (AMC), Amsterdam (W16_088 # 16.108). 
Histological grading was available for seven subjects with four low-grade 
and three high-grade tumors. 
 
 
Table 1. Overview of section sizes per dataset. The minimum and maximum section sizes are 










All uneven-numbered sections of a patient were collected for hematoxylin 
and eosin (H&E) staining, followed by digitalization in a high-resolution 
slide scanner (Ultra Fast Scanner, Philips, Best, The Netherlands) and 
histological annotation. All even-numbered sections were used for 3D-MSI.  
 
The sections were de-paraffinized with 3 xylene washes (5, 10, and 10 min), 
subsequently rinsed 3 times with HPLC-grade ethanol (each 2 min) followed 
by 2 UHPLC-grade water washes of 5 min (all solutions are from Biosolve 
Chimie SARL, Dieuze, France). To undo the crosslinking induced by 
formalin fixation, antigen retrieval was performed with citric acid at 10 mM 
and pH 6.0 (Sigma-Aldrich, Zwijndrecht, The Netherlands) at 121°C for 20 
minutes using the Antigen Retriever 2100 (Aptum Biologics, UK). This was 
followed by applying 15 layers of 20 µg/mL water-dissolved porcine trypsin 
(Sigma-Aldrich) using a SunCollect pneumatic sprayer (SunChrom GmbH, 
Germany) with a constant 10 µL/min flowrate, track spacing of 1 mm, nozzle 
height of 25 mm, and a nozzle speed of 900 mm/min. Samples were then 
incubated at 37°C for 17 hours in an airtight box containing 100 mL of 1:1 
water:methanol. Afterward, 7 layers of 5 mg/mL alpha-cyano-4-
hydroxycinnamic acid (Sigma-Aldrich) in 50% acetonitrile (Biosolve Chimie 
SARL, Dieuze, France) and 0.2% trifluoroacetic acid (Sigma-Aldrich, 
Zwijndrecht, The Netherlands) was applied using the same SunCollect 
sprayer with increasing flowrates of 10, 20, 30, and 40 µL/min for the first 
four layers, and 40 µL/min for the remaining layers with a track spacing of 
2 mm, nozzle height of 25 mm, and a nozzle speed of 1390 mm/min before 
performing MSI experiments.  
 
On all ITO slides, 1 µL of 1 mg/mL intact cytochrome c (from equine heart, 
Sigma-Aldrich) was deposited manually before trypsin application to 





All sections were imaged at 50 µm raster size on a rapifleX MALDI-ToF/ToF 
instrument[15] (Bruker Daltonik GmbH, Bremen, Germany) across an m/z 
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range of 800-3000 in positive-ion reflectron mode. The laser was focused for 
each tissue separately and scanned across a 50x50 µm2 area with 1000 laser 
shots summed for each position. Laser intensity was adjusted off tissue to 
obtain similar intensities for the matrix across all measurements (~4x104). 
Typical mass resolution was on average 20,000 for a single pixel (55,200 data 
points per spectrum). During acquisition the data was processed with 
centroid peak detection (S/N ≥ 5, 0.5 Da peak width, 78% height), Savitzky-
Golay smoothing (width of 0.01 m/z, and 1 cycle), and TopHat baseline 
subtraction. The instrument was calibrated before each measurement by 
using red phosphorus as a calibration agent. At the end of acquisition, a fast-
access-data-file was automatically created by resampling the spectra to 80% 






In total, fourteen bladder cancer specimens each consisting of 20 sections 
spaced 10 µm apart were measured (Figure 1A). The reduced MSI data were 
imported into SCiLS Lab 2016a (SCiLS, Bremen, Germany) without baseline 
removal for further analysis. In SCiLS Lab, the MSI data was also co-
registered with the corresponding H&E stains that were previously 
annotated by trained pathologists (Figure 1C). All spectra were total-ion-
count (TIC) normalized for all subsequent steps. Peak picking was 
performed on the exported overall average spectrum (Figure 1B) in 
mMass[117] (35 precision baseline correction, Gaussian smoothing with a 
window size of 0.5 Da and 2 cycles, deisotoping with an isotope mass 
tolerance of 0.1 Da and intensity tolerance of 50%, and at last peaks were 
picked with an S/N threshold of 3 using the complete height of the peaks) 
and matrix and trypsin related peaks were removed by mass matching, with 
0.2 Da tolerance, a spectrum that has been acquired off-tissue. With this peak 
list, consisting of 298 masses, the maximum intensity in each peak interval 
(200 ppm) was exported for every patient and section in tabular form from 






Outliers were determined by employing two methods: the first uses the 
cytochrome c spots that were applied on each slide to monitor digest efficacy. 
Principal Component Analysis (PCA) was performed on the mean spectra 
from the cytochrome c spots of each dataset and a 95% error ellipse was 
calculated in the first two-component space. Any cytochrome c 
measurements that were outside the 95% error ellipse are considered outliers 
and the two sections belonging to this slide were taken out. The second 
outlier method is based on the assumption that the z-directed distribution of 
the intensity of a molecule has a certain consistent gradient that can be 
modeled and tested by regression (Figures 2C and 2F). A quadratic function 
(linear and higher-order polynomials showed lower Akaike information 
indices) is fitted for each m/z (x = z-position; y = intensity) and the section 
that has the maximum absolute residual value is recorded. A section is 
considered an outlier if the residual frequency is higher than the 99% 
confidence interval (=2.58 standard deviations from the mean) of the 
expected by-chance mean frequency (Formula 1): 
 
 
Formula 1: 𝑟𝑒𝑠𝑖𝑑𝑢𝑎𝑙 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑 =
# 𝑜𝑓 𝑝𝑒𝑝𝑡𝑖𝑑𝑒 𝑚𝑎𝑠𝑠𝑒𝑠
# of sections
+  2.58 ∗
                             





By combining these two methods a list of outlier sections is obtained that 
were not considered for further data analysis. 
 
Assessment of the spatial correlation of MSI data with histological 
annotations was done using both an unsupervised and a supervised 
approach. For the unsupervised method, probabilistic Latent Semantic 
Analysis (pLSA) was applied in SCiLS Lab on all pixels of all datasets using 
ten components. The pLSA component coefficients for all pixels were then 
exported to R where they were investigated for their discriminatory power 
between tumor and non-tumor regions using the Receiver Operating 
Characteristic (ROC) analysis. The optimal cut-off for a pLSA component 
was derived from the ROC curve using Youden’s index, a summary measure 
for the maximum potential effectiveness of a biomarker.[139] 
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For the supervised analysis, a linear discriminant analysis was carried out in 
SCiLS Lab using the six patients for whom both clinical data as well as 
annotations were available. A leave-one-out cross-validation was used to 
assess the accuracy of the model. This model was then applied to annotate 
previously not-annotated tumor regions within a seventh patient of whom 
the clinical data was also available. 
 
All subsequent statistical analyses were performed on the log-transformed 
data in order to approximately conform it to normal distribution. 
 
To investigate sampling bias for the detection of low- or high-grade specific 
peptides in tumor regions when only one section is considered per patient, a 
section is chosen randomly for each patient followed by statistical testing 
using a Student t-test for significant differences between both grades. Masses 
that had a p-value ≤ 0.05 were considered statistically significant. This was 
repeated 1000 times. A mass was considered statistically significant if its 
frequency was higher than 6.2% (a binomial test gave that threshold where 
the true probability of success was > 5%). To monitor also the directionality 
of the significant difference, the non-log scaled fold-changes in intensity 
were recorded as well. 
 
To test the number of sections needed to cover the molecular information of 
a full dataset, the average spectrum of a complete dataset was determined 
first. Then, a defined number of sections were randomly selected 100 times, 
their average spectrum was calculated, and the Pearson correlation 
coefficient of the resulting spectrum to the full sample’s average spectrum 
was determined. It was investigated how the correlation changed with an 
increasing number of randomly selected sections. The relevance of the 
sampling position was investigated by calculating the average distance 
between the selected sections.  
 
Three-dimensional visualizations of MSI datasets and H&E stacks were 








Results and Discussion 
 
Within this study, 20 consecutive sections have been measured for fourteen 
bladder cancer specimens by mass spectrometry imaging (MSI) with the aim 
to obtain a more representative molecular description of each patient (Figure 
1A). The samples were provided as FFPE tissues and the molecular class of 
interest was the proteome that requires the use of antigen retrieval and 
proteolytic digestion, in order to obtain a peptide spectrum (Figure 1B). The 
efficacies, and therefore reproducibility, of these two sample preparation 




Figure 1. Overview of study data. MSI was used to measure 20 evenly spaced consecutive 
sections of 14 bladder cancer patients, labeled 1-14 (A). The average peptide spectrum across 
all datasets is shown in (B) with red triangles indicating the 298 peak-picked masses. 
Annotated H&E stains for dataset 1 and 5 are shown in (C). Three-dimensional visualizations 
of the H&E stains and the MSI-data of the same dataset are shown in (D). 
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Outliers and reproducibility of sample preparation 
 
In this study, we developed two methods for outlier detection: one based on 
evaluating digestion efficacy and the second on checking data consistency 
within 3D-MSI datasets. The first criterion, proposed by Erich et al.[84], uses 
a spot of intact cytochrome c being applied on each slide before digestion. 
We extend this idea by applying a principal component analysis on the 
resulting spectra to identify outliers as data points that lay outside the 95% 
error ellipse in the first two principal components space (Figures 2A and 2D). 
Applying this criterion on all datasets separately declared 11 slides, and 
hence a total of 22 sections out of the 280 sections as outliers – a dropout rate 
of < 8%.  
 
The second criterion is based on the assumption that each molecular 
distribution follows a consistent gradient in the z-direction and can be 
modeled mathematically by regression. Consequently, sections whose mass 
signals consistently produce high deviations from that gradient can be 
considered outliers (Formula 1 and Figures 2C and 2F). For these 
calculations, the mean spectrum of the whole section was used from the 
datasets that had not previously been removed by the cytochrome c quality 
control. When applying this criterion, a total of 34 sections were classified as 
outliers from the remaining 258 sections, giving a reproducibility rate of 87%. 
An example that shows the complementarity of both approaches is given in 
Figures 2A and 2C, where sections were labeled as outliers from whom it 
was known that they adhered during antigen retrieval to the back of another 
slide.  This would not have been detectable by the cytochrome c check only. 
 
As stated before, these two criteria were combined to cover all the possible 
technical incidences. After cytochrome c (22 outlier sections) and regression 
(34) filtering, this resulted in a total of 56 outlier sections out of the 280 
sections, and therefore in a reproducibility rate of 80%. Given that the 
samples are FFPE and therefore require more extensive sample preparation, 
we consider these dropout rates acceptable thereby allowing further 







Figure 2. Outlier detection strategies for two example datasets (patient 1 in B and patient 5 in 
E, corresponding H&E stains can be found in Figures 1C and 3). The outlier detection was 
based on evaluating digest efficacy (A and D) and a residual detection in a z-directed 
regression (C and F). The cytochrome c based outlier detection relies on the principal 
component analysis (PCA) of the digest spectra of cytochrome c, which was spotted on every 
slide before proteolytic digestion. Slides having scores in the first two-component PCA space 
outside the 95% error interval are considered outliers, shown as red dashed lines (A). Single 
sections are considered outliers if a critical number of mass channels show a deviating 
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Figure 3. H&E stains from dataset 1 (A) and dataset 5 (B) from which data is shown in Figures 
2 and 5. 
 
 
Spatial correlation of MSI data with histology 
 
The first question is related to the spatial correlation of the MSI data with the 
histology to ensure that any molecular signature for the tumor is indeed from 
the tumor. To this end, both unsupervised and supervised multivariate 
analyses were performed.  
 
For the unsupervised approach, probabilistic Latent Semantic Analysis 
(pLSA) was performed with ten expected components. This analysis was 
performed on all datasets simultaneously, except for the previously 
eliminated outliers.  To quantify the specificity of these components for 
representing tumor areas, five non-tumor regions were defined manually for 
each dataset as negative controls (Figure 4A, the dataset shown is one with 
the most outliers due to sample preparation problems. Corresponding 





The pLSA data for all annotated regions was then exported to R where the 
discriminatory power of the components to discern tumor from non-tumor 
regions was investigated by a ROC analysis (Figures 4B and 4C). The area-
under-the-curve of component 10 with a value of 0.883 was found to exhibit 
the highest discriminatory power. Youden’s index was then used to 
determine the optimal cut-off for the pLSA coefficients, here 0.1, resulted in  
a sensitivity of 84%, a specificity of 79%, and overall accuracy of 79% (Figure 
4C). This could help to determine whether there is a tumor present in a 
sample when annotations are not available. 
 
The same purpose was pursued with the supervised analysis, especially 
since from the fourteen datasets measured there are only six where 
annotated H&E images were available. These six datasets were used to train 
and validate a linear discriminant analysis model to distinguish between 
tumor and non-tumor tissue. Leave-one-out cross-validation estimated the 
mean model’s accuracy to be 88%, 9 percentage points more accurate than 
the unsupervised approach, with a sensitivity of 94% and a specificity of 
68%. Similarly to Inglese et al.[42], such classifiers can be extremely useful to 
annotate 3D-MSI datasets on a per-pixel basis when annotations are not 
available for all H&E images. The supervised classifier was used to annotate 
the tumor in these sections that are then incorporated in all subsequent 
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Figure 4. Unsupervised multivariate analysis and correlation with tumor regions. The 
unsupervised multivariate analysis was performed on the single pixels using probabilistic 
latent semantic analysis (pLSA). (A) Shows the visualization of the pLSA-component 10 in 
dataset 1 (corresponding H&E stains can be found in Figures 1C and 3) where high coefficients 
seem to co-localize well with tumor (red) and low coefficients with non-tumor regions (blue). 
(B) The coefficients of component 10 are shown for all samples in a boxplot illustrating the 
difference in coefficients for both histological entities. The red line depicts the optimal 
threshold at 0.1, which was determined using a ROC analysis and Youden’s index (C). 
 
 
Influence of sample bias on biomarker discovery 
 
Histopathological annotations, resulting in increased cellular and 
histological specificity, have been key for success in MSI-based studies in 
order to increase statistical sensitivity for biomarker discovery.[27] However, 
only one section per patient has been usually used for this purpose and 
might affect the results due to a sampling bias.[140] In our case, a 3D volume 
has been collected per patient allowing for the investigation of how this 
sampling would influence biomarker discovery. To investigate this we 
randomly sampled a single section per patient a 1000 times and resolved 
which masses are found significantly different (P ≤ 0.05) in each run between 
the high- and low-grade patients. On average 3 masses were found 
significantly discriminating in each run. Although this number looks 
comparable to the sensitivity of other MSI studies[141], the overlap and 
therefore the reproducibility between the runs was low. This is illustrated in 




across the 1000 runs was ~1%. However, from a statistical point of view, a 
frequency of > 6.2% is already significantly higher than by chance. Applying 
this frequency threshold to the found discriminating masses resulted in 
seven peptides being significantly discriminating (Figures 5A and 5B). Of 
these, six are more intense in high-grade and one in low-grade based on their 
fold changes (Figure 5C). Nevertheless, the overall low frequencies of masses 
indicate that there can be significant influences on biomarker discovery due 
to sampling bias, especially if the cohort is small. Inversely, if the cohort is 
larger, such as in classical 2D-MSI studies, the variance due to patient-related 
differences is expected to be much bigger than compared to sampling bias 
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Figure 5. Investigation of sampling bias on biomarker discovery for high-grade cancers. To 
test sampling bias, one section per patient was randomly sampled and mass channels were 
tested for discriminating power between the two grades. This was repeated 1000 times and 
the frequency of significance for every mass channel was recorded. The histogram gives an 
overview of the range of frequencies (A). A binomial test found a frequency of > 6.2% 
significantly constant (red line). (B) Shows the significantly frequent mass channels above the 
red dashed line. The fold changes of the frequent peptides indicate whether they are more 
present in high- or low-grade tumors (C). Example distributions of two frequent mass 
channels are shown in (D) for a high-grade specific (left) and a low-grade specific peptide 
(right) where tumor regions are indicated in red (corresponding H&E stains for datasets 1 and 










Sampling extent and representativeness   
 
To overcome the consequences of sampling bias based on one section, we 
examined for our samples how many sections need to be sampled to acquire 
a sufficiently accurate representation of the complete sample. Therefore, the 
average spectrum of the full dataset was calculated as a reference. From an 
increasing number of randomly sampled sections the average spectra were 
calculated and their correlation to the reference determined by the Pearson 
correlation coefficient. As expected, the results show that tissues are better 
represented as more sections are taken, shown in Figure 6A for dataset 1. If 
we consider a correlation coefficient of 0.99 sufficiently representative, then 
four sections for dataset 1, which is 29% of the sections, need to be measured. 
Overall, the minimum sampling percentage for all datasets was on average 
33% (Figure 6C). Interestingly, we observed a batch of higher minimum 
percentages for datasets 4-9 in Figure 6C. Given a randomized experimental 
setup with respect to the clinical data of the patients and the numbering of 
the datasets in chronological order of their measurement, this means that the 
calculated minimum sampling percentage is most likely also influenced by 
time-related technical variation. Moreover, considering a 20% dropout rate 
according to our outlier detection (Figure 2), we recommend that a minimum 
of 41% of the volume of a sample is required to be measured.  With respect 
to the sampling position, there is no correlation between the average distance 
between the randomly sampled sections and the achieved correlation to the 
ground truth, i.e., it does not matter from where in the 3D volume the 
sections are sampled (Figure 6B). This is most likely due to the fact that our 
sample volumes are relatively small (200 µm in depth). If thicker tissues are 
being analyzed, it can be argued that representative sampling has to be done 
equally spread throughout the whole sample as the influence of tissue 
heterogeneity is larger in these cases. Even though our samples are small,  
this analysis does show the potential of determining for large patient studies 
how many sections are required for an accurate representation of the whole 
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Figure 6.  Relation between sampling extent and coverage of molecular information. For every 
patient, a ground truth spectrum was calculated by averaging all spectra across all sections. 
This is repeated for a randomly sampled number of sections ranging from 1 to the maximum 
number of sections available in a sample. The Pearson correlation coefficient was calculated 
between this and the ground truth spectrum for quantifying the deviation of the subsampled 
data from the full data. This was repeated 100 times. The result for dataset 1 is shown in (A). 
The green line shows the minimum number of sections needed to achieve a sufficient high 
similarity to the ground truth (correlation coefficient ≥ 0.99, red dashed line). For the same 
dataset, (B) depicts the relation between the correlation coefficient and the physical distance 
in z-direction among the sampled sections. The minimum number of sampling extent varies 





Fourteen 3D-MSI datasets of FFPE human bladder cancer resections have 
been created by measuring the peptides produced following in situ tryptic 
digestion. These datasets have been used to set-up a data analysis pipeline 
for this type of data. In a first step, we proposed two methods for the 
detection of outliers: intact cytochrome c to monitor digest efficacy, and 
regression to evaluate consecutive section consistency. Both analyses show 
that our data is robust and as a consequence, we observed a consistently high 
spatial correlation with histology. The acquired 3D datasets allowed for the 
investigation of sampling bias on biomarker discovery and sample 
representativeness. We observed significant effects due to sampling bias on 
the final peak list of grade-associated peptides. To address sampling bias, we 




sufficiently representative for one sample (sparse 3D-MSI). This strategy can 
be transferred easily to other studies in order to determine a minimum 
sampling rate, which can significantly reduce the experimental workload of 
3D-MSI studies. However, in order to obtain a more complete representation 
of one tumor, our approach has to be extended to samples from multiple 
sites of the tumor.[143] Both, multi-site sampling as well as sparse 3D-MSI 
could potentially be guided by a preceding non-invasive ex-vivo imaging of 
the whole tumor or individual subsamples (micro-CT, etc.).[144] Even then a 
reliable biomarker discovery has to be matched with a sufficient number of 
subjects involved. Although in our case the sampling pool was too small to 
provide results with high statistical power, the reported pipeline can be 
regarded as a starting point to further investigate and extend other multi-
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Esophageal adenocarcinoma (EAC) is a complex and heterogeneous disease 
that originates from Barret's esophagus. Progression from this precursor 
lesion via low-and high-grade dysplasia to EAC involves a large variety of 
genetic alterations.  
 
These alterations do not occur throughout the whole tissue but are very 
localized events.  This makes EAC both a molecularly and spatially complex 
disease. Both complexity scales have to be captured to gain more information 
about EAC progression and the accompanying molecular changes. One of 
these changes is in N-glycan expression as the glycosylation pathway is one 
of the mechanisms affected during esophageal adeno-carcinogenesis. 
 
In this chapter, we employ mass spectrometry imaging (MSI) to spatially 
resolve N-glycan changes during EAC. To this end, 24 human FFPE 
esophageal resections spanning all stages of EAC progression were studied. 
The heterogeneous nature of the disease makes that both 3D-MSI, as well as 
2.5D-MSI, have been employed. First, 3D-MSI was used to image one patient 
per stage to determine the number of sections needed to be representative of 
the whole volume. This analysis showed that a total of 4 sections out of 20 
were needed. This subset was measured for the remaining patients and is 
called 2.5D-MSI.  
 
Analyses of the 2.5D-MSI datasets revealed 3 differentially expressed N-
glycans across the EAC stages. These N-glycans were classified as high-
mannose and tetra-antennary N-glycans whose presence could be explained 
by publically available gene expression data. Combined these data confirm 
that N-glycosylation plays a vital role in EAC progression. As the role of 
glycosylation is gaining more interest in cancer research our results also 
show the added value of combining localized MSI analysis with gene 













Esophageal cancer is a very aggressive disease that ranks sixth in mortality 
among all cancers, making it one of the deadliest cancers worldwide. Even 
though advances have been made in both diagnosis and therapeutics it still 
has a poor 5-year survival rate of 15-25%.[145-147] Amongst esophageal cancers, 
the incidence of esophageal adenocarcinoma (EAC) has risen dramatically 
over the last decades.[148] 
 
EAC follows from Barret's esophagus or Barret’s mucosa as a precursor 
lesion via low- and high-grade dysplasia.[124, 149, 150] Barrett's esophagus (BE) 
results from a chronic injury caused by acid and bile reflux whereby 
squamous epithelium of the esophageal mucosa undergoes a metaplastic 
transformation into columnar intestinal epithelium.[149-151] The progression 
from BE to EAC is accompanied by a large number of alterations in 
oncogenic pathways and tumor suppressor genes that play a role and vary 
individually in EAC development.[152] The complexity of EAC is also 
reflected in its molecular heterogeneity at the spatial level.[124, 153] 
Understanding the local molecular alterations underlying adeno-
carcinogenesis in the context of tissue-based molecular and cellular 
heterogeneity will aid in understanding the mechanisms of cancer onset, its 
prevention, and the development of personalized therapy.[153] Especially, 
since EAC precursor lesions are very locally confined events, gaining insight 
into the molecular sequence of events that lead to EAC requires an in situ 
molecular analysis. 
 
One technique that allows both the label-free detection of molecular species 
and records their spatial distribution is mass spectrometry imaging (MSI).[27, 
154] It allows the simultaneous detection of a large number of compounds 
from a broad range of molecular classes (small molecules, lipids, peptides, 
proteins, and modifications thereof). In cancer research, it has already been 
used to determine metabolite and lipid profiles in therapy-resistant 






In EAC research, MSI has already been employed for the identification of 
specific peptide profiles for EAC stages in 300 patients assembled in tissue 
microarrays.[158] In two other studies on intact proteins, MSI identified 
several proteins that could be linked to EAC development, EAC metastases, 
patient prognosis, and chemotherapy response.[159, 160] A study using 
desorption ionization MSI investigated lipid profiles of metastatic and non-
metastatic primary tumors, which allowed the metastatic status of patients 
to be predicted with 98% accuracy.[161] 
 
Glycosylation is one of the most important posttranslational modifications 
of proteins[162] and aberrant glycosylation has been found implicated in 
various types of cancers and EAC during malignant transformation.[163] N-
linked glycans have already been studied by MSI in ovarian and breast 
cancer. It allowed the differentiation between tumor and non-tumor 
regions[164] and identified N-glycans specific for late-stage compared to the 
early-stage ovarian cancer like sialylated structures and oligomannose N-
glycans.[165] In breast cancer, MSI found the specific presence of 
polylactosamine glycans in triple-negative, metastatic, and advanced HER2+ 
patients[166] and F(6)A4G4Lac1, a core-fucosylated tetra-antennary glycan, 
correlated with poor clinical outcome.[167] 
 
The aforementioned studies provided evidence for the added benefit of MSI 
in differentiating different stages as well as finding new potential markers. 
Although these results are encouraging, most MSI studies limit themselves 
to one section per sample. However, EAC is a heterogeneous disease, and 
analyzing only a single section can lead to discrepancies with a full tissue 
analysis.[39] It is important to overcome the sampling bias and analyze either 
the whole 3D volume or measure a representative subset of sections of the 
whole tissue (2.5D), as we have shown previously.[68, 85] 
 
In this research, we have employed 3D matrix-assisted laser/desorption 
ionization MSI (MALDI-MSI) followed by 2.5D MALDI-MSI to investigate 
N-glycan changes in human esophageal adeno-carcinogenesis (Figure 1). A 
total of 24 formalin-fixed paraffin-embedded (FFPE) esophageal resections 
of low-grade dysplasia (n=2), high-grade dysplasia (n=3), low- and high-
grade dysplasia (n=1), intra-mucosal cancer (n=8), adenocarcinoma (n=4), 
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and adenocarcinoma with metastases (n=6) were analyzed to ensure a 
complete overview of all steps of EAC adeno-carcinogenesis. 
 
 
Figure 1. Schematic overview of the different steps in the experimental set-up for a single EAC 
stage. First, 3D-MSI is employed on one patient sample, and outliers are removed on a slide 
and section basis. After outlier removal the number of sections needed to be representative of 
the whole volume is determined. This subset is used is for subsequent 2.5D-MSI of the 
remaining patients and used for further analyses where the resulting images are overlaid with 







Human formalin-fixed, paraffin-embedded (FFPE) esophagus tissues of 24 
patients were collected and analyzed in this study. Of these 24 patients, 2 
had low-grade dysplasia, 3 had high-grade dysplasia, 1 had low- and high-
grade dysplasia, 8 had intra-mucosal cancer, 4 had adenocarcinoma, and 6 
had adenocarcinoma with metastasis. From each patient, 20 consecutive 
sections with a thickness of 5 µm and spaced 10 µm apart were provided by 
the Amsterdam Medical Center (Amsterdam, Netherlands) on indium tin 




Ltd, Loveland, Colorado, USA) with two sections per slide. For all patients, 
histological annotations and grading were available and did not require 
approval from the relevant Institutional Ethics Committee under applicable 





Xylene, HPLC grade ethanol, UHPLC grade water, ULC/MS - CC/SFC 
acetonitrile, and ULC/MS - CC/SFC grade methanol were purchased from 
Biosolve Chimie SARL (Dieuze, France). Citric acid monohydrate, α-cyano-
4-hydroxycinnamic acid (CHCA, C10H7NO3), and trifluoracetic acid (TFA, 
Chromasolv®, for HPLC), and RNAse B (Glycoprotein Standard from 
bovine pancreas) were purchased from Sigma-Aldrich (Zwijndrecht, The 
Netherlands). PNGase F was purchased from N-Zyme Scientifics, LLC 
(Doylestown, Pennsylvania, USA). Eosine-Y, Alcoholic was purchased from 
Avantor® Performance Materials B.V. (Deventer, the Netherlands). 
Hematoxylin solution modified according to Gill and entellan® new was 
purchased from Merck KGaA (Darmstadt, Germany), and coverslips were 





Sections were pre-heated on a heating plate at 60°C for an hour to melt the 
paraffin. Immediately after, the sections were washed with xylene for 1 x 5 
minutes and 2 x 10 minutes to remove the paraffin, followed by subsequent 
washes with ethanol (3 x 2 minutes) to remove the lipids and with water (2 
x 5 minutes) to rehydrate the sections. Antigen retrieval was subsequently 
performed to undo the cross-linking induced by the formalin fixation with a 
10 mM citric acid solution at pH 6.0 using the Antigen Retriever 2100 (Aptum 
Biologics, Southampton, UK) at 121°C for 20 minutes. Sections were then 
washed with water (2 x 1 minute) and after drying of the slides 1 µL of 1 
µg/µL RNAse B was spotted on the slides as quality control. This was 
followed by application of 15 layers of 200 ng/µL water-dissolved PNGase 
F using a SunCollect pneumatic sprayer (SunChrom Wissenschaftliche 
Geräte GmbH, Friedrichsdorf, Germany) at a flowrate of 10 µL/min, nozzle 
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speed of 900 mm/min, nozzle height of 25 mm, and a track spacing of 1 mm 
where the slides were randomized. This was followed by incubation of the 
slides for 3 hours in an incubation box containing 50% methanol at 37°C. 
Afterward, the sections were coated in the same randomized order with 8 
layers of 5 mg/mL CHCA in a 50% acetonitrile solution containing 0.2% TFA 
using an automated TM-sprayer (HTX Technologies, LLC, North Carolina, 
USA) at 30°C with a flowrate of 0.05 mL/min with no drying time in between 
the layers. 
 
Following MSI analysis, sections were H&E stained by first washing off the 
matrix from the slides in 70% ethanol for 2 x 3 minutes, followed by a 3-
minute wash with Milli Q. Slides were stained with hematoxylin (3 minutes), 
washed for 3 minutes with tap water to remove excess hematoxylin, then 
stained with eosin (30 seconds), washed again for 3 minutes to remove excess 
eosin, followed by a 1-minute ethanol wash and a 30 seconds xylene wash 
before attaching coverslips to the slides using Entellan as a mounting 
medium. Optical images of the H&E tissue section were acquired using an 
optical microscope scanner (Mirax Desk, Zeiss, Jena, Germany).  For each 
patient, one unmeasured section was stained and annotated by a pathologist. 
These annotations were then transferred via image co-registration onto the 





All sections were measured on a rapifleX MALDI-ToF/ToF instrument 
(Bruker Daltonik GmbH, Bremen, Germany) in positive-ion mode at a spatial 
resolution of 50 µm in the m/z range of 800-4000 by scanning the laser across 
a 45x45 µm2 area and summing 200 shots per pixel. To obtain reproducible 
results, detector checks were performed at the start of each measurement day 
and laser intensity and height were optimized on the matrix intensity off 
tissue to obtain similar intensities for the matrix (~ 3–4x104). Before each 
measurement, the instrument was calibrated using red phosphorus as a 
calibration agent. During acquisition, the data were automatically processed 
with Savitzky-Golay smoothing (0.01 m/z width, and 1 cycle), TopHat 
baseline subtraction, and centroid peak detection (0.05 m/z peak width, S/N 






In total four complete 3D-MSI datasets were acquired (one for each EAC 
stage) and imported into separate SCiLS Lab MVS (SCiLS, Bremen, 
Germany) files for outlier detection and representativity analysis using a 200 
data points precision for the TopHat baseline subtraction. Spectra were TIC 
normalized and a ± 0.2 Da interval width per peak was chosen for further 
analysis. The overall average mass spectrum was exported to mMass[117] for 
peak picking to reduce the amount of data prior to processing. Peak picking 
in mMass was preceded by 35 precision baseline correction, Gaussian 
smoothing with a 0.3 Da window size and 1 cycle, crop from 920 to 3000 m/z, 
de-isotoping with a 70% intensity tolerance and 0.2 Da isotope mass 
tolerance. Peaks were picked that had an S/N ≥ 5 at maximum height in the 
mean spectrum and matrix peaks were manually removed. The resulting list 
was imported back into SCiLS and used for further analysis. Maximum 
intensities for each peak interval (0.2 Da) in the peak list for every section 
was afterward exported from SCiLS in tabular form for sequential outlier 
detection and representation analysis in RStudio (version 1.2.1335). 
 
MSI data from the RNAse B quality control were imported into separate (per 
3D dataset) SCiLS Lab MVS files for outlier detection employing a 200 
precision TopHat baseline subtraction. All spectra were normalized to TIC 
for subsequent analysis and peak picking was performed in mMass on the 
exported overall average mass spectrum employing the same settings as for 
the 3D-MSI data. Peaks were picked that had an S/N ≥ 3 and a relative 
intensity threshold ≥ 1% (with respect to the base peak) at maximum peak 
height and matrix peaks were removed by expelling those peaks in the 800-
2500 m/z range that have a mass defect ≤ 0.3. The resulting list was imported 
back into SCiLS and used for further analysis. 
 
Outlier slides or sections were identified based on two outlier strategies that 
were previously reported by our group.[85] For identifying outlier slides, 
Principal Component Analysis (PCA) was performed on the TIC normalized 
mean spectra of the RNAse B quality control spots per slide using a 95% error 
ellipse in the first two-component space. All RNAse B measurements outside 
this ellipse were considered outliers and corresponding slides were removed 
from further analysis. To identify outlier sections, we use a method that 
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investigates the intensity gradient of single m/z values in the z-directionality 
within a 3D model. Per m/z value, a regression is fitted to a linear or quadratic 
function, depending on which one fits best according to the Akaike 
information index, and the section with the maximum residual is recorded. 
This is repeated for all m/z values and the sections that have a residual count 
higher than a set threshold (usually, ≥ 99% confidence interval of expected 
by-chance mean frequency, formula 1) are considered outliers. A 
combination of these two outlier detection methods resulted in a list with 
outlier sections that were not considered for further analysis. 
 
 
Formula 1: 𝑟𝑒𝑠𝑖𝑑𝑢𝑎𝑙 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 𝑡ℎ𝑟𝑒𝑠ℎ𝑜𝑙𝑑 =
# 𝑜𝑓 𝑁−𝑔𝑙𝑦𝑐𝑎𝑛 𝑚𝑎𝑠𝑠𝑒𝑠
# of sections
+  2.58 ×
                             





Based on the 3D-MSI data after outlier detection, it was determined how 
many sections per patient are sufficiently representative of the whole 
volume. This was done as described previously by our group.[85] Briefly, an 
average spectrum is created for the whole 3D volume and each section. The 
mean spectrum of the whole 3D volume is then compared to the average 
spectra obtained for a subset of n random sections and repeated 100 times. 
Subsequently, this is repeated with n+1 sections until all sections have been 
used. For each combination, a Pearson correlation coefficient is calculated 
and the first number of sections that reaches 0.99 defines the minimum 
number of sections required. 
 
In total 20 2.5D-MSI datasets were acquired that included RNAse B quality 
controls for each measured slide. All sections were individually recalibrated 
by selecting one spectrum per section containing N-glycans covering the 
whole spectral range. These spectra were then manually recalibrated in 
flexAnalysis (Bruker Daltonik GmbH, Bremen, Germany) using a mass list 
containing known molecular signals up to m/z 2540 (Table 1) and a 500 ppm 
tolerance to be able to recalibrate the low-intensity masses at the higher end 
of the spectrum. The calibration constants of each recalibrated spectrum 
were copied and pasted to all other spectra from the same respective dataset. 




annotated H&E images to obtain average mass spectra for the annotated 
regions of interest and imported into a SCiLS Lab MVS file for analysis using 
200 precision TopHat baseline subtraction. Spectra were TIC normalized and 
a ± 0.2 Da interval width per peak was chosen for further analysis. The 
overall average mass spectrum was exported to mMass[117] for peak picking 
to reduce the amount of data prior to processing. Peak picking in mMass was 
preceded by 35 precision baseline correction, Gaussian smoothing with a 0.3 
Da window size and 1 cycle, crop from 920 to 3000 m/z, de-isotoping with a 
70% intensity tolerance and 0.2 Da isotope mass tolerance. Peaks were picked 
that had an S/N ≥ 5 at maximum height in the mean spectrum and matrix 
peaks were manually removed. The resulting list was imported back into 
SCiLS and used for further analysis. 
 
 
Table 1. Overview of the masses used for recalibration of the 20 2.5D-MSI datasets. 
 
 
MSI data from the RNAse B quality control was also imported into SCiLS 
Lab MVS files for outlier detection employing a 200 precision TopHat 
baseline subtraction. All spectra were normalized to TIC for subsequent 
analysis and peak picking was performed in mMass on the exported overall 
average mass spectrum with the same settings as for the 3D-MSI RNAse B 
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data (see above). The resulting list was imported back into SCiLS and used 
for further analysis. The RNAse B quality controls were checked for outliers 
in the 2.5D-MSI data as described above. Potential outliers were removed 
from the data and annotations for each section were grouped to obtain an 
average spectrum for every patient and section. 
 
The SCiLS data was exported using the maximum mean value for every peak 
to investigate if N-glycans show significant differences in abundance over 
the different stages. Statistical analyses were performed in RStudio (version 
1.2.1335). Analysis of Variance was employed, for which the data were log-
transformed to comply with the requirement of normally distributed data. 
As the data is composed of 20 patients with technical replicates, mixed effect 
models were calculated with the EAC stage as a fixed effect, the patient as a 
random effect, and the measured glycan-signal abundance as a dependent 
variable. The obtained results were corrected for multiple testing using the 
Benjamini-Hochberg method with a false-discovery-rate threshold of 0.1. 
Post-hoc pairwise comparisons were corrected using Tukey’s method. 
 
N-glycans were tentatively identified by mass-matching them with a 
maximum tolerance of 60 ppm to N-glycans reported in the literature (Table 




Table 2. Overview of the tentatively identified N-glycan masses by mass-matching with 
reported N-glycans by Heijs et al.[169] 
 
 
The publically available gene expression datasets from the NCBI GEO 
Datasets repository (https://www.ncbi.nlm.nih.gov/gds) on esophageal 
cancer GSE1240[171] and GSE2444[172] were searched for known enzymes to be 
involved in N-glycan synthesis (Tables 3 and 4 respectively).[173, 174] In case of 
dataset GSE1240, the enzymes were re-coded to be 0 (absent), 0.5 (marginal), 
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Table 3. Overview of the enzymes involved in N-glycan synthesis in publically available 
dataset GSE1420. Per protein, there were either one or multiple reference ID’s found and per 



















Table 4. Overview of the enzymes involved in N-glycan synthesis in publically available 
dataset GSE2444. Per protein, log-ratio values were given between the sample and healthy 
control. These values are positive if they are upregulated in the sample or negative if they are 





Determination of the minimum number of sections per patient 
using 3D MALDI-MSI 
 
Imaging the tissues of all patients in 3D is time-consuming work that merits 
the question if it provides sufficiently more information over a random 
subset of sections to be worthwhile. We set out to determine the minimum 
number of sections statistically representative of a whole 3D volume. For this 
purpose, one full 3D-MSI dataset was acquired for every EAC stage (Figures 
1 and 2).  
 
Possible outlier slides were removed based on RNAse B quality controls that 
were present on each slide. To do so, a PCA was performed on the RNAse B 
spectra and a 95% error ellipse was calculated in the first two principal 
component space for each dataset. The results show that the enzyme worked 
similarly on almost all slides (Figure 3) except for one slide in the low- + 
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high-grade dysplasia dataset, which exhibited a lower digestion efficiency 
and was therefore removed. Further outlier sections were determined based 
on the intensities in a 3D volume that are assumed to follow a certain 
gradient in the z-direction.[85] This was tested by a regression analysis based 
on either a linear or quadratic function. Sections that show the highest 
residual value over all m/z values more than by chance (formula 1) are 
considered outliers. On average two sections were classified as outliers per 
3D-MSI dataset through the application of this criterion (Figure 3). 
 
For each of these 3D-MSI datasets, the aim was to subsequently find a set of 
representative sections (2.5D) for the whole tissue. An average spectrum was 
calculated as a reference for every 3D-MSI dataset for this purpose. Then this 
reference spectrum was compared to the average spectrum calculated from 
an increasing number of randomly chosen sections by determining the 
similarity between these two profiles using Pearson correlation. Taking a 
minimum coefficient of 0.99, 2-3 sections were found to be sufficiently 
representative for a 3D-MSI dataset (Figure 3), which is 10-20% of the total 
sample size of 20 sections. To have a consistent amount of sections for all 
EAC stages, we decided to measure 4 sections for all remaining patients, as 
2 sections were placed on one single slide. For the 2.5D-MSI, the two slides 










Figure 2. Examples of 3D and 2.5D mass spectrometry imaging data. (A) 3D visualization of 
the adenocarcinoma dataset consisting of 20 sections with the corresponding representativity 
analysis. (B) Spectra and visualization of one 2.5 MSI dataset consisting of 4 sections along 
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Figure 3. Overview of the 3D-MSI outlier and representativity analysis results. (A) Example 
of the RNAse B-based PCA-based outlier detection with a 95% error ellipse where the crosses 
indicate each measured RNAse B spot. Next to it is the RNAse B spectrum of the outlier (red) 
shown as an overlay with the normal RNAse B spectrum (black). (B) Table summarizing the 
outlier detection results of all 3D-MSI datasets using the different outlier detection 
mechanisms as well as the representativity analysis results. 
 
 
Mapping N-glycan changes during esophageal adeno-
carcinogenesis 
 
Glycosylation plays an important role in disease progression during 
esophageal adenocarcinogenesis (EAC).[163] Mapping these changes in 
glycosylation could provide useful insights into disease progression and 
offer a new approach to EAC staging. We, therefore, performed 2.5D N-
glycan MSI by measuring 4 sections from 20 patients with different stages of 
esophageal adenocarcinogenesis: 2 low-grade dysplasias, 3 high-grade 
dysplasias, 7 intra-mucosal cancers, 3 adenocarcinomas, and 5 
adenocarcinomas with metastases. Annotations by an experienced 
pathologist were used to extract the N-glycan profiles from dysplastic and 





After peak picking, the N-glycan profile contained 108 signals. A mixed-
effect model was calculated for every m/z species of the N-glycan profile 
followed by multiple testing corrections to determine if there are 
differentially expressed N-glycans between the different EAC stages. This 
analysis identified three m/z species all of which were found at higher 




Figure 4. Boxplots of the three N-glycans found to be more abundant in the adenocarcinomas 
with the corresponding visualization of said molecule in the 2.5D-MSI dataset below. The 
different stages have been abbreviated to LG (low-grade dysplasia), HG (high-grade 
dysplasia), IC (inter-mucosal cancer), C (adenocarcinoma), and CM (adenocarcinoma with 
metastases). (A) Boxplot of m/z 933.4, tentatively assigned to man3 (H3N2), with its 
corresponding structure and p-value. (B) Boxplot of m/z 1095.4, tentatively assigned to man4 
(H4N2), with its corresponding structure and p-value. (C) Boxplot of m/z 2393.9, tentatively 
assigned to a tetra-antennary N-glycan (H7N6), with its corresponding structure and p-value. 
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One of these, m/z 933.4 (P = 0.037), was found to distinguish EAC patients 
with metastases from those without. It was tentatively assigned to Man3 
(H3N2, Hex3HexNAc2 + 1Na, ∆53.6 ppm) based on prior literature.[169, 170] 
The other two N-glycans that were more present in adenocarcinomas 
compared to dysplasia and intramucosal carcinoma were m/z 1095.4 and m/z 
2393.9 (both P = 0.098), tentatively assigned to Man4 (H4N2, Hex4HexNac2 
+ 1Na, ∆9.1 ppm)[169, 170] and tetra-antennary N-glycan H7N6 (Hex7HexNAc6 
+1Na, ∆20.9 ppm)[21, 168, 169], respectively.   
 
Next, we investigated two publically available gene expression datasets 
from esophageal cancer, GSE1420[171] and GSE2444[172] for alterations in 
enzymes that play a role in the synthesis of the found N-glycans[173, 174] in 
EAC onset or progression (Figure 5A). In this meta-analysis, we found 
almost all of these enzymes increased in cancer compared to normal 




Figure 5. Meta-data analyses of the enzymes involved in the synthesis of N-glycans H3N2, 
H4N2, and H7N6. The different stages have been abbreviated to N (normal), C 
(adenocarcinoma), and CM (adenocarcinoma with metastases). (A) Heatmap showing the up- 
or down-regulation of enzymes involved in the synthesis of N-glycans H3N2, H4N2, and 
H7N6 in publically available datasets GSE1240 and GSE2444. The heatmap shows that almost 
all enzymes are up-regulated in adenocarcinoma.  (B) Overview of which enzymes play a role 







In this study, we aimed to find N-glycans related to the carcinogenesis of 
esophageal adenocarcinoma (EAC) using MALDI mass spectrometry 
imaging (MSI). To achieve this we analyzed 24 human samples covering the 
whole sequence of EAC progression. We had 20 consecutive sections 
available for every patient to account for the spatial heterogeneity of this 
process in all 3 dimensions. 
 
As EAC is a heterogeneous disease, one patient per stage was imaged in 3D 
first to determine the number of sections needed to be representative for the 
whole volume. 
 
We performed a previously established outlier detection procedure[85], 
which determined that on average 2.5 sections needed to be removed per 
MSI dataset or in total 10 sections of the 80 sections measured giving an 
87.5% reproducibility rate. This was considered an acceptable dropout rate 
since previous and similar experiments on bladder cancer (also FFPE and use 
of enzymatic digest) gave a lower reproducibility rate of 80%.[85]  
 
The representativity analysis determined that 2–3 sections could be 
considered sufficiently representative (Pearson correlation > 0.99) for the 
stack of 20 consecutive sections. It is clear that this stack is itself not fully 
representative for the entire tissue sample or the patient, but it can be 
considered an approximation. Sampling bias will continue persisting as long 
as invasive sampling methods are used. 
 
These data were subsequently used to identify differentially expressed N-
glycans between the different EAC stages. A total of 108 signals were 
detected in the mass range typical for N-glycans. Of these, 52 (48%) could be 
tentatively assigned to N-glycans (Table 2), demonstrating the reliability of 
the employed protocol to detect N-glycans. 
 
Three N-glycans (H4N2, H7N6, Man3) were found statistically altered 
between some of the stages of EAC with all of them being more abundant in 
advanced stages (carcinoma or carcinoma with metastasis) compared to 
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dysplasia or intra-mucosal carcinoma. Man3 is a pauci-mannose and has, 
like man4, been already reported in breast and colorectal cancer, and at 
higher levels in malignant colorectal tumors.[170, 175] In ovarian cancer tissues 
it was however found that this N-glycan was specific for adipose tissue 
instead of the tumor region.[164] H4N2 is a high-mannose N-glycan that has 
already been found at higher levels in breast and colorectal cancer[170, 175], 
which is in line with our results. This N-glycan is usually the lowest in 
abundance of the high-mannose group making this an interesting finding 
since we did not observe other high-mannose N-glycans to be altered. The 
other N-glycan, H7N6, was found at higher levels in stage IA3 lung 
adenocarcinoma and hepatocellular carcinoma with almost no presence in 
normal tissue.[21, 168] 
 
While this confirms the role of these glycans in carcinogenesis, we strived for 
shedding light on the mechanisms of glycosylation in esophageal cancers. 
Based on the aforementioned results, we investigated two publically 
available gene expression datasets for alterations in enzymes that play a role 
in the synthesis of the found N-glycans. In line with our observations, the 
involved enzymes MAN, MGAT1, and MGAT2 were up-regulated in 
esophageal cancer compared to healthy tissues. 
 
In particular, higher levels of the MAN enzymes, which are responsible for 
trimming down N-glycans starting from a structure with 9 mannoses to 
Man3 (Figure 5B), could explain the higher levels of Man4 and Man3 
observed by us in EAC tissues. Several enzymes, including the MGAT1 and 
MGAT2 enzymes, facilitate the synthesis of H7N6. These enzymes also 
exhibit an increase from healthy to cancer, with MGAT1 being further 
increased in cancer with metastases (Figure 5A). These enzymes add a 
GlcNAc to the core of N-glycans ending up with a Man3 with two GlcNAc 
residues forming the base for all multi-antennary N-glycans, where MGAT4 
and MGAT5 add the final two GlcNAc to form tetra-antennary N-glycans 
(Figure 5B). To get to the final structure, the terminal GlcNacs need to be 
galactosylated, which is done by the B3GAL and B4GAL enzymes. 
 
This study shows that N-glycan MSI data can be contextualized with gene 
expression data from studies with similar research questions. Relating these 




understanding of the role of glycosylation in EAC progression and gives 
evidence at multiple levels that specific N-glycosylation plays an important 





MALDI-MSI of N-glycans was successfully applied to 24 FFPE human 
esophageal resections spanning the different stages of esophageal 
adenocarcinogenesis to gain more insight into N-glycosylation changes 
during disease progression. As EAC is a heterogeneous disease, one patient 
per stage was imaged in 3D first to determine the number of sections needed 
to be representative for the whole volume. We found that 2-3 sections were 
needed to be representative leading to 4 sections being used for the 2.5D-MSI 
of the remaining patients. These data were subsequently used to identify 
differentially expressed N-glycans between the different EAC stages. In total 
3 N-glycans were found to be more abundant in the carcinoma stages whose 
presence could be explained by meta-analyses of publically available gene 
expression data. This evidence at multiple levels confirms that specific N-
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Biological tissues are molecularly complex volumetric systems. To 
understand these tissues techniques are needed that can capture this 
complexity while maintaining the spatial information. This demands 
innovative new ways to increase dimensionality, both molecular and spatial, 
of existing techniques.  
 
Increasing dimensionality is not only needed for research to gain a deeper 
understanding of complex living systems, in the industry this increase is 
needed to provide a better diagnosis to patients. A complete tissue gives a 
better view of the spread of the disease and its severity based on the 
molecular information.  The work presented in this thesis formed a central 
part of the ITEA 3D Pathology project where the aim was to determine if we 
can valorize this increased dimensionality by moving 3D pathology to the 
clinic. In this light, we set out to not only investigate the potential of moving 
from 2D H&E, which is the standard cell-based analysis used in pathology, 
to 3D H&E but also the addition of molecular information using 3D-MSI. For 
this purpose, the consortium consisted of a variety of members focusing on 
either acquiring the data, data analysis, visualization of the data, as well as 
setting up a platform to teach pathologists in training how to work and 
interpret 3D data. All these aspects are of importance and require the 
collaboration of scientists, companies, and pathologists if 3D pathology is to 
be established in the clinic.  This is how the impact of MSI can be increased 
beyond the fundamental insights it can provide and provides the possibility 
to valorize the research described in this thesis. 
 
The scope of this thesis was to investigate the 3D capabilities of MSI and its 
potential for use in the clinic. Several steps have been added to the 
valorization potential of this work. The first important step towards clinical 
translation is to increase the compatibility of MSI with clinical tissues. These 
tissues are often FFPE tissues that require new sample preparation methods 
to be developed to allow molecules to be imaged that are still reflective of 
the biology. Preferably, these sample preparations not only retain the 
biological information but are also fast to conform to the standard pathology 
times of analyzing tissues and provide a diagnosis to the patient. In chapter 
2 we, therefore, investigated the effect formalin fixation has on the lipidome 
of tissues. These results will aid clinicians in better understanding the lipid 





The next phase towards the translation of MSI to the clinic is having 
established data analysis methods that allow a uniform analysis of the data 
across different clinics. This is needed to prevent a patient from obtaining 
diagnosis X at clinic A while with the same data gets diagnosis Y at clinic B. 
Within M4I we therefore set-out to develop strategies to manage multi-
patient data that are presented in chapter 3. Our proposed methods ensure 
that the data used for analysis are without outliers. This is important in a 
clinic as outliers can steer model-based diagnosis into a false direction 
thereby reducing the accuracy of diagnosis using this type of data. In 
addition, the pipeline can be easily transferred to other types of 3D-MSI data 
sets acquired at different labs. As it is also applicable to single patient 3D-
MSI studies or even multi-patient 2D-MSI studies, it makes an ideal starting 
point towards a uniform data analysis pipeline for clinical 3D-MSI data. This 
universal application of our method, which is demonstrated in chapter 4, is 
not only interesting in a clinical setting but also for companies when they are 
considering providing 3D-MSI services.  
 
The previously mentioned aspects are all important to translate 3D-MSI to 
the clinic. Its true implementation, however, requires integration with the 
pathologist standard method, which is H&E staining. Within our 
consortium, we have closely interacted with several pathologists and they 
also stated that the only way they envision 3D-MSI in their labs is when it 
can be integrated with their H&E’s placed next to it and co-registered to 
allow regions of interest to be quickly defined. 
 
In view of the above, we collaborated with our consortium partners at 
Phillips to visualize our MSI data together with the H&E data in their digital 
pathology system. This was successful and allows both data to be 
investigated at the same time, however, the data is visualized as single 
sections instead of a complete 3D volume. As the goal was to integrate both 
modalities as 3D volumes, we additionally collaborated with PS-Medtech 
who was also a part of the ITEA 3D Pathology consortium. They provide 3D 
visualization workstations that are already implemented in hospitals to 
visualize and interact with 3D CT and MRI data. This interaction is an added 
value as it will allow the radiologist to explore the 3D image and see what 




interactive visualize it. Once this was in place we worked towards the end 
goal of the ITEA 3D pathology, namely visualize a 3D H&E volume next to 
a 3D MSI volume for the clinical pathology community. This was challenging 
as two different modalities had to be placed into one coordinate system. In 
addition, they have to be in the same orientation and coordinate system to 
ensure the H&E section and the MSI section are the same ones. If these 
challenges could be overcome we would have everything in place to bring 
3D Pathology, and thus 3D-MSI, to the clinic. To this end, a 3D H&E volume 
was generated at the AMC and with M4I we provided the corresponding 
3D-MSI volume. At the end of the ITEA project, we were able to visualize 
both volumes in one space and interactively go through both volumes 
simultaneously.  
 
This shows that 3D Pathology can be translated to the clinic but it requires 
interdisciplinary cooperation of scientists, pathologists, and companies. 
Only when they all work together across the boundaries of their own 
disciplines and interests, 3D-MSI analysis can become applicable in clinical 





































Mass spectrometry imaging (MSI) has seen widespread use in clinical 
research to study the molecular complexity of tissue on a spatial level. These 
have contributed to new insights into tumor heterogeneity and molecular 
changes that happen before their effect is visible on a cellular level. This latter 
can aid in obtaining clean margins during tumor resection. Although these 
studies all provide valuable information they are often performed on a two-
dimensional scale where one or a few sections are used. These 2D studies are 
prone to sampling bias as the molecular complexity of biomedical tissues 
cannot be captured in a few sections, especially when they are all from the 
same sampling site. To thoroughly capture the molecular complexity of a 
single tissue it should be investigated as a whole. The development of faster 
instrumentation and automated sample preparation devices has led MSI to 
do exactly this by the emergence of 3D-MSI. Current 3D-MSI studies are 
mostly done on a single biomedical tissue as these studies require often 
extensive sample preparation and measurement time, even with the recent 
advancements. However, to gain a deeper understanding of biological 
processes underlying diseases, multi-patient 3D-MSI studies are needed. The 
work presented in this thesis is focused on the sample preparation and data 
analysis strategies that are needed to enable 3D-MSI of biomedical tissues to 





Biomedical tissues are often formalin-fixed and paraffin-embedded (FFPE) 
as this allows for long-term storage. This required new sample preparation 
methods to make MSI compatible with these types of tissues. Over the years 
protocols have been developed and applied for 2D-MSI studies. However, 
these protocols are often long and require enzymatic digestion of the tissue. 
Applying this to 3D-MSI studies, and especially multi-patient studies, make 
that acquisition of the data will take a long time maybe even up to months. 
A less extensive sample preparation, and consequently quicker, is therefore 
preferred. 
 
The introduction of a new method that allows for lipid detection and only 
requires a quick washing step and matrix application seems to be promising 
for speeding up 3D-MSI of FFPE tissues. To be able to apply this for 3D-MSI, 
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or even 2D-MSI studies, it has to be certain that the obtained lipidome is 
reflective of the tissues.  We found by doing an in-depth study that class-
specific changes are happening during formalin-fixation. In particular the 
cross-linking of amine-containing lipids resulting in depletion of these 
molecules. Taken into account that these tissues would also undergo 
paraffin-embedding, which can result in a loss of lipids, it is hard to say how 
reflective the lipidome still is. Even though it can still be used to differentiate 
different disease states the biological meaning of the lipids are hard to 
discern and need to be rationalized. When antigen retrieval can be optimized 
for lipids, thereby undoing the cross-linking, the amine-containing lipids 
will be detectable again and the lipidome will be (more) reflective of the 
tissue biology.  
 
As lipids are not yet suitable for 3D-MSI studies, enzymatic digestion of the 
tissues is needed to obtain biological reflective molecules that can be imaged. 
These digestions involve a lot of manual sample handling which can lead to 
technical variation. In addition, the efficiency of the enzymatic digestion can 
vary per section. This has already been shown in 2D-MSI studies and makes 
reproducibility a challenge, though is often achieved as 2D-MSI allows for 
multiple sections from different patients to be prepared in a single day. 
 
 
Quality controls and data analysis  
 
Reproducibility is an even bigger impediment in 3D-MSI studies, where at 
most one single tissue can be prepared in one go given that the amount of 
sections is not too high and different tissues are prepared on different days. 
When the 3D dataset is too large a single tissue will even be prepared on 
different days. This spread in preparation and acquisition can lead to 
technical variations and consequential outliers. It is therefore imperative that 
sample preparation and data analysis strategies are adapted to ensure 
reproducibility and removal of outliers. One way to achieve this is by 
incorporating quality controls during sample preparation to monitor 
important steps in the protocol prone to variation. This predicament was 
solved by incorporating a quality control before trypsin application which 
was the enzyme used to digest 14 FFPE bladder cancer resections. The 




and the removal of those slides with a too high variance in digestion 
efficiency.  
 
Incorporation of these quality controls is a great step forward in realizing 
multi-patient 3D-MSI studies. It allows the removal of outliers thereby 
increasing the confidence that variations found in a single 3D volume or 
between patients are biological. As sample preparation is paving the way, 
new data analysis strategies are needed to finish it. Established data analyses 
are insufficient to handle the large amounts of data generated in 3D-MSI 
studies. To extract the wealth of information in these studies, data analysis 
strategies are needed that first remove outliers and next reduce the amount 
of data to those molecules that are biologically interesting, e.g. those 
molecules that are different between disease states, or specific for a certain 
histological region.  
 
One way to incorporate outlier removal during data analysis can be by 
making use of incorporated quality controls during sample preparation as 
has been shown by the usage of cytochrome c. These kinds of controls are 
useful for tracking digestion outliers, however, they do not indicate outliers 
due to other technical variations. Data analysis should, therefore, 
incorporate other strategies as well to pick these out. We have overcome this 
conundrum by developing an outlier detection method that uses the z-
regression of single masses as each mass will follow a certain trend in the z-
direction. Beneficial of this kind of method is that it depends only on the 
intensities of the molecules in the single sections, thereby picking out both 
outliers due to sample preparation variation as well as those due to 
instrument variation. Although this is a robust strategy, along with quality 
controls, in removing all possible outliers the downside is that it only works 
when molecules are present throughout the whole volume. When volume 
sizes get bigger or more heterogeneous, and molecules are present in only 
parts of the tissues, this strategy will not work and different detection 











As strategies are slowly developing to analyze 3D-MSI data, and potentially 
venture into combination with other imaging modalities, it is becoming the 
new trend in MSI. This increase in 3D-MSI data also begs the question of 
whether 3D-MSI is needed and is worth the effort. Yes, biomedical tissues 
are molecularly complex and heterogeneous volumes but is imaging of the 
whole volume the only option to gain a complete overview of this 
complexity and avoid sampling bias. An investigation into the sampling bias 
indeed shows that restricting an investigation to one single tissue section 
induces sampling bias and can greatly affect the discovery of new 
biomarkers, highlighting once again the need to measure more sections per 
sample to overcome this. However, this does not necessarily mean the whole 
tissue as was observed after a representativeness analysis which gave a 
minimum number of sections needed to be molecularly representative of the 
whole tissue. This number was less than 50% of the total volume for two 
different datasets consisting of two different types of tissue (bladder cancer 
and esophageal adenocarcinoma) and molecules of interest (peptides and N-
glycans) providing evidence that 3D-MSI might not be needed to map the 
molecular heterogeneity and something in between, like 2.5D MSI, is 
sufficient. Indeed there might be reasons for 3D-MSI, other than mapping 
the molecular complexity that does require a complete volume to be 
investigated. However, this has so far not been shown. Although 3D-MSI is 
thus a hot and shiny new thing, its added value over a more extensive 2D-


















Mass spectrometry imaging (MSI) has become an established tool to spatially 
resolve the molecular make-up of biomedical tissues. Advancements in 
sample preparation and instrumentation facilitated the development of 3D-
MSI to gain a deeper understanding of the spatially and molecular 
complexity of biological processes in tissues. In this thesis, the challenges in 
applying 3D-MSI in biomedical research are appraised and addressed. The 
newly developed methods and insights are subsequently applied to multi-
patient cohort studies. 
 
In chapter 1 the readers are introduced to the field of 3D-MSI and its current 
challenges. These challenges are focused on two major fields: sample 
preparation and data analysis. For both, aspects are discussed that have to 
be considered when performing 3D-MSI experiments as well as the obstacles 
that still need to be resolved. One of these aspects is how to prepare single-
cells for 3D-SIMS or serial sections for 3D-DESI and 3D-MALDI MSI to 
enable 3D reconstruction. The experimental design is also discussed and 
how to ensure reproducibility, which follows into outlier detection as one of 
the challenges to be addressed during data analysis. In addition, 3D image 
reconstruction and multimodal 3D-imaging are reviewed. Overall, this 
chapter provides considerations that aid in setting-up optimal (multi-
patient) 3D-MSI studies.  
 
Chapter 2 focuses on the sample preparation of FFPE samples and whether 
lipids can be a possible new mine to dig for 3D-MSI of these biomedical 
tissues. An in-depth analysis of the lipid classes detectable from fresh frozen 
and formalin-fixed mouse and rat kidney tissues gave noticeable differences. 
Amine-containing lipids are completely depleted upon fixation which is 
most likely a result of cross-linking of these lipids with each other and with 
amine-containing proteins. As a result of this depletion, an increase in 
sulfatides and cholesterol is observed. These class-specific lipid changes 
upon formalin fixation show that care has to be taken when biological 
statements are made based on lipid data from FFPE tissues. 
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In chapter 3 some of the challenges in the analysis of 3D-MSI data are being 
tackled by setting up a pipeline for handling multi-patient 3D-MSI data. We 
first acquired 14 3D-MSI datasets of human FFPE bladder cancer resections 
by enzymatic digestion with trypsin. This data was used to develop novel 
outlier detection methods that are based on quality controls incorporated in 
the sample preparation as well as the acquired data itself. Using cytochrome 
c on every slide as quality control to monitor digestion efficiency enables the 
identification of those slides on which digestion performed insufficiently.  
The other outlier method is based on the z-directed regression of the single 
masses thereby identifying those outliers based on other technical variations. 
Combined, these two methods resulted in 56 sections being marked as 
outliers out of the total 280 sections measured, giving a realistic 
reproducibility rate of 80%. Besides these, a method was developed to 
determine the minimum amount of sections needed to be molecularly 
representative of the whole tissue. This showed that for this type of sample 
33% of the sections is sufficient to be representative of the whole tissue. This 
strategy can be transferred to other studies and aid in reducing the workload 
of 3D-MSI studies. 
 
This expertise is applied in chapter 4 where N-glycan changes are 
investigated during esophageal adeno-carcinogenesis. To this end, 24 
human FFPE esophageal resections have been digested using PNGase F to 
obtain N-glycosylation profiles. Due to the heterogeneous behavior of 
disease progression, one patient per stage was first imaged in 3D and the 
number of representative sections was determined. This showed that 4 
sections are required and subsequently used for the remaining patients and 
called 2.5D-MSI. Analysis of the 2.5D-MSI data marked 3 N-glycans as more 
abundant in adenocarcinoma whose presence could be explained by 
publically available gene expression data. This combination of data 
demonstrates that specific N-glycosylation plays an important role and both 
MSI and gene data should be combined to gain a deeper understanding of 
this process.  
 
The work presented in this thesis all contributes to one major valorization 
aspect portrayed in chapter 5. The potential of implementing 3D-MSI in the 
clinic as part of 3D pathology is described and requires collaboration 






Massaspectrometrie imaging (MSI) is een gangbare techniek geworden om 
de moleculaire samenstelling van biomedische weefsels ruimtelijk vast te 
leggen. Verbeteringen in monster voorbereiding en instrumentatie 
bevorderde de ontwikkeling van 3D-MSI om een dieper inzicht te verkrijgen 
in de ruimtelijke en moleculaire complexiteit van biologische processen in 
weefsels. In dit proefschrift worden de uitdagingen bij het toepassen van 3D-
MSI in biomedisch onderzoek beoordeeld en aangepakt. De nieuw 
ontwikkelde methoden en vergaarde inzichten zijn vervolgens toegepast in 
cohortonderzoeken met meerdere patiënten.  
 
In hoofdstuk 1 maken de lezers kennis met het veld van 3D-MSI en zijn 
huidige uitdagingen. Deze uitdagingen zijn gericht op twee grote gebieden; 
monster voorbereiding en data-analyse. Voor beide worden die aspecten 
behandeld die in consideratie genomen moeten worden wanneer een 3D-
MSI experiment wordt uitgevoerd als mede de knelpunten die nog moeten 
worden opgelost. Eén van die aspecten is hoe een enkele cel voor 3D-SIMS 
of seriële secties voor 3D-DESI en 3D-MALDI geprepareerd moet worden 
om 3D reconstructie mogelijk te maken. De experimentele opzet en hoe 
reproduceerbaarheid gewaarborgd kan worden wordt ook bediscussieerd. 
Dit vloeit uit in detectie van uitbijters als één van de uitdaging die 
geadresseerd moet worden tijdens data-analyse. Daarnaast worden 3D 
beeldreconstructie en multimodaal 3D-imaging beoordeeld. Globaal biedt 
dit hoofdstuk overwegingen die helpen bij het opzetten van (multi-patiënt) 
3D-MSI onderzoeken. 
 
Hoofdstuk 2 focust zich op monster voorbereiding van FFPE monsters en de 
vraag of een mogelijk nieuwe manier om 3D-MSI van deze biomedische 
weefsels te versnellen de detectie van lipiden is. Een uitgebreide analyse van 
de detecteerbare lipidenklassen van vers ingevroren en formaline gefixeerde 
nierweefsels van muis en rat leverde aanmerkelijke verschillen op. Amine-
bevattende lipiden zijn volledig afgenomen en is waarschijnlijk het gevolg 
van verweving van deze lipiden met zichzelf als mede met amine-
bevattende eiwitten. Door deze afname is een toename in sulfaten en 
cholesterol geconstateerd. Deze klassen-specifieke lipide verandering door 
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formaline fixatie laat zien dat voorzichtigheid in acht moet worden genomen 
wanneer biologische verklaringen worden genomen gebaseerd op lipide 
data van FFPE weefsels.  
 
In hoofdstuk 3 worden enkele uitdagingen in de data-analyse van 3D-MSI 
data aangepakt door het opzetten van een procedure voor het aanpakken 
van multi-patiënt 3D-MSI data. Eerst hebben we 14 3D-MSI 
gegevensbestanden van menselijk FFPE blaaskanker resecties vergaard door 
enzymatische digestie met trypsine. De verkregen data werd gebruikt om 
nieuwe detectiemethoden voor uitbijters te ontwikkelen die gebaseerd zijn 
op kwaliteitscontroles geïntrigeerd in de monster voorbereiding als ook de 
verweven data zelf. Gebruik maken van cytochroom c op elk glaasje als 
kwaliteitscontrole voor digestie efficiëntie faciliteerde de identificatie van 
die glaasjes waar dit ontoereikend was. De andere uitbijter detectiemethode 
is gebaseerd op de regressie van individuele massa’s in de z-directie waarbij 
uitbijters, ontstaan door technische variatie, worden aangemerkt. 
Gecombineerd wezen deze methoden 56 secties van de in totaal gemeten 280 
secties aan als uitbijter wat resulteert in een reproduceerbaarheid van 80%. 
Daarnaast was er een methode ontwikkeld om het minimale aantal secties te 
bepalen dat nodig is om op een moleculair niveau representatief te zijn voor 
het gehele weefsel. Dit gaf aan dat voor onze monsters 33% van de secties 
voldoende is om representatief te zijn voor het gehele weefsel. Deze strategie 
kan worden overgebracht naar andere onderzoeken en zo bijdragen aan het 
verminderen van de werklast van 3D-MSI onderzoeken.   
 
Hoofdstuk 4 ziet de toepassing van de eerder ontwikkelde data-analyse 
methoden in een biologisch onderzoek naar N-glycan verandering tijdens 
slokdarm adeno-carcinogenese. Hiervoor zijn 24 menselijke FFPE slokdarm 
resecties enzymatisch gedigesteerd met PNGase F om N-glycans te 
verkrijgen. Vanwege het heterogene karakter van de ziekteprogressie is één 
patiënt per stadium eerst gemeten in 3D en het aantal representatieve secties 
bepaald. Dit wees uit dat 4 secties nodig zijn en dit is vervolgens gebruikt 
voor de resterende patiënten en wordt 2.5D MSI genoemd. Analyse van de 
2.5D-MSI data duidde 3 N-glycans aan die meer aanwezig waren in 
adenocarcinomen en waarvan de aanwezigheid verklaard kon worden door 
publiek toegankelijk genexpressie data. Deze combinatie van data toont aan 




genetische data gecombineerd moet worden om een dieper inzicht te 
vergaren in dit proces.  
 
Het werk dat gepresenteerd is in dit proefschrift draagt allemaal bij aan één 
belangrijk valorisatie aspect weergegeven in hoofdstuk 5. De 
realiseerbaarheid om 3D-MSI in de kliniek te implementeren als onderdeel 
van 3D pathologie is beschreven en vereist de samenwerking van 
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